https://astx.com/jhoti-h-high-throughput-structural-proteomics-using-x-rays-trends-in-biotechnology-19-no-10-2001-s67-s71-doi-10-1016s0167-77990101791-7/ 2016-11-29T13:55:11+00:00 monthly 0.2 https://astx.com/jhoti-h-structural-genomics-lessons-to-be-learnt-drug-discovery-today-6-no-24-2001-1261-1262-doi-10-1016s1359-64460102114-6/ 2016-11-29T13:54:50+00:00 monthly 0.2 https://astx.com/murray-c-w-verdonk-m-l-the-consequences-of-translational-and-rotational-entropy-lost-by-small-molecules-on-binding-to-proteins-journal-of-computer-aided-molecular-design-16-no-10-2002-741/ 2023-12-21T12:05:12+00:00 monthly 0.2 https://astx.com/carr-r-jhoti-h-structure-based-screening-of-low-affinity-compounds-drug-discovery-today-7-no-9-2002-522-527-doi-10-1016s1359-64460202245-6/ 2016-11-29T13:53:28+00:00 monthly 0.2 https://astx.com/carr-r-hann-m-the-right-road-to-drug-discovery-modern-drug-discovery-5-no-4-2002-45-48/ 2016-11-29T13:53:10+00:00 monthly 0.2 https://astx.com/blundell-t-l-jhoti-h-et-al-high-throughput-crystallography-for-lead-discovery-in-drug-design-nature-reviews-drug-discovery-1-2002-45-54-doi-10-1038nrd706/ 2016-11-29T13:52:47+00:00 monthly 0.2 https://astx.com/yon-j-jhoti-h-high-throughput-structural-genomics-and-proteomics-where-are-we-now-targets-2-no-5-2003-201-207-doi-10-1016s1477-36270302348-1/ 2016-11-29T13:51:44+00:00 monthly 0.2 https://astx.com/williams-p-a-et-al-crystal-structure-of-human-cytochrome-p450-2c9-with-bound-warfarin-nature-424-no-6947-2003-464-468-doi-10-1038nature01862/ 2016-11-29T13:51:10+00:00 monthly 0.2 https://astx.com/watson-p-verdonk-m-hartshorn-m-j-a-web-based-platform-for-virtual-screening-journal-of-molecular-graphics-and-modelling-22-no-1-2003-71-82-doi-10-1016s1093-32630300137-2/ 2016-11-29T13:49:42+00:00 monthly 0.2 https://astx.com/verdonk-m-l-et-al-improved-protein-ligand-docking-using-gold-proteins-structure-function-and-bioinformatics-52-no-4-2003-609-623-doi-10-1002prot-10465/ 2016-11-29T13:49:20+00:00 monthly 0.2 https://astx.com/van-montfort-r-l-m-et-al-oxidation-state-of-the-active-site-cysteine-in-protein-tyrosine-phosphatase-1b-nature-423-2003-773-777-doi-10-1038nature01681/ 2016-11-29T13:48:59+00:00 monthly 0.2 https://astx.com/sharff-a-jhoti-h-high-throughput-crystallography-to-enhance-drug-discovery-current-opinion-in-chemical-biology-7-no-3-2003-340-345-doi-10-1016s1367-59310300062-0/ 2016-11-29T13:48:36+00:00 monthly 0.2 https://astx.com/hartshorn-mj-astexviewer-a-visualisation-aid-for-structure-based-drug-design-journal-of-computer-aided-molecular-design-16-no-12-2003-871-881-doi-10-1023a1023813504011/ 2016-11-29T13:48:16+00:00 monthly 0.2 https://astx.com/frederickson-m-vuillard-l-et-al-novel-selenium-containing-non-detergent-sulphobetaines-tetrahedron-letters-44-no-43-2003-7925-7928-doi-10-1016j-tetlet-2003-09-004/ 2016-11-29T13:47:56+00:00 monthly 0.2 https://astx.com/congreve-m-s-et-al-a-rule-of-three-for-fragment-based-lead-discovery-drug-discovery-today-8-no-19-2003-876-877-doi-10-1016s1359-64460302831-9/ 2016-11-29T13:47:33+00:00 monthly 0.2 https://astx.com/congreve-m-s-et-al-detection-of-ligands-from-a-dynamic-combinatorial-library-by-x-ray-crystallography-angewandte-chemie-international-edition-42-no-37-2003-4479-4482-doi-10-1002a/ 2016-11-29T13:47:10+00:00 monthly 0.2 https://astx.com/birch-l-et-al-sensitivity-of-molecular-docking-to-induced-fit-effects-in-influenza-virus-neuraminidase-journal-of-computer-aided-molecular-design-16-no-12-2003-855-869-doi-10-1023a1023/ 2016-11-29T13:46:37+00:00 monthly 0.2 https://astx.com/published-data-suggests-supergens-nipent-as-part-of-a-combination-preparative-regimen-is-active-in-allogeneic-bone-marrow-transplant-patients-with-myelodysplastic-syndrome/ 2016-11-28T14:42:18+00:00 monthly 0.2 https://astx.com/supergen-completes-submission-of-new-drug-application-nda-for-orathecin-as-an-oral-treatment-for-pancreatic-cancer/ 2016-11-28T14:41:43+00:00 monthly 0.2 https://astx.com/supergen-announces-resignation-of-dr-craig-rosenfeld-to-pursue-start-up-opportunity/ 2016-11-28T14:41:12+00:00 monthly 0.2 https://astx.com/supergen-inc-announces-filing-of-registration-statement-for-public-offering-of-shares-of-common-stock/ 2016-11-28T14:40:40+00:00 monthly 0.2 https://astx.com/supergen-announces-interim-data-from-dacogen-phase-iii-clinical-study-in-myelodysplastic-syndrome/ 2016-11-28T14:40:10+00:00 monthly 0.2 https://astx.com/supergen-inc-announces-intent-to-withdraw-the-registration-statement-for-public-offering-of-shares-of-common-stock/ 2016-11-28T14:39:41+00:00 monthly 0.2 https://astx.com/supergen-acquires-european-marketing-authorizations-for-nipent-from-pfizer/ 2016-11-28T14:39:08+00:00 monthly 0.2 https://astx.com/webcast-alert-supergen-presentation-at-informed-investors-biotechhealthcare-virtual-forum-to-be-webcast-on-thursday-february-26-2004-1030-am-et/ 2016-11-28T14:38:41+00:00 monthly 0.2 https://astx.com/supergen-reports-2003-fourth-quarter-and-year-end-financial-results/ 2016-11-28T14:37:53+00:00 monthly 0.2 https://astx.com/published-study-results-show-low-dose-outpatient-dosing-schedule-of-dacogen-useful-in-patients-with-hematological-malignancies/ 2016-11-28T14:37:07+00:00 monthly 0.2 https://astx.com/supergen-announces-private-placement-of-34-million-of-stock-and-warrants/ 2016-11-28T14:36:34+00:00 monthly 0.2 https://astx.com/supergen-releases-interim-data-clarification-from-dacogen-phase-iii-clinical-study-in-myelodysplastic-syndrome-following-analystinvestigator-conference-call/ 2016-11-28T14:43:07+00:00 monthly 0.2 https://astx.com/supergen-note-holders-release-10-6-million-in-escrowed-funds/ 2016-11-28T14:35:22+00:00 monthly 0.2 https://astx.com/astex-the-wellcome-trust-the-institute-of-cancer-research-and-cancer-research-technology-announce-major-cancer-drug-discovery-collaboration/ 2016-11-28T14:34:48+00:00 monthly 0.2 https://astx.com/supergens-new-drug-application-for-orathecin-rubitecan-capsules-accepted-by-fda-for-filing/ 2016-11-28T14:34:22+00:00 monthly 0.2 https://astx.com/supergen-reports-results-from-dacogen-phase-iii-study-in-myelodysplastic-syndromes-mds/ 2016-11-28T14:33:49+00:00 monthly 0.2 https://astx.com/astex-achieves-second-milestone-in-alzheimers-drug-discovery-collaboration-with-astrazeneca/ 2016-11-28T14:33:18+00:00 monthly 0.2 https://astx.com/supergen-nasdaq-supg-will-webcast-its-scientific-review-and-corporate-update-for-investors/ 2016-11-28T14:32:04+00:00 monthly 0.2 https://astx.com/supergen-announces-fda-acceptance-of-rolling-nda-request-for-dacogen/ 2016-11-28T14:31:31+00:00 monthly 0.2 https://astx.com/supergen-reports-2004-first-quarter-financial-results/ 2016-11-28T14:30:54+00:00 monthly 0.2 https://astx.com/supergen-announces-study-of-novel-regimen-using-nipent-for-hematopoietic-stem-cell-transplantation-published-in-journal-of-bone-marrow-transplantation/ 2016-11-28T14:30:26+00:00 monthly 0.2 https://astx.com/supergen-provides-additional-analysis-of-response-data-from-phase-iii-study-of-dacogen-in-mds/ 2016-11-28T14:29:53+00:00 monthly 0.2 https://astx.com/supergen-submits-cmc-to-fda-as-first-component-of-rolling-new-drug-application-for-dacogen/ 2016-11-28T14:29:22+00:00 monthly 0.2 https://astx.com/supergen-reports-promising-results-from-phase-i-study-of-dacogen-and-carboplatin-for-treatment-of-advanced-solid-tumors/ 2016-11-28T14:28:47+00:00 monthly 0.2 https://astx.com/supergen-reports-results-of-ongoing-studies-of-nipent-in-combination-therapies-for-chronic-lymphocytic-leukemia-and-low-grade-b-cell-lymphomas/ 2016-11-28T14:28:17+00:00 monthly 0.2 https://astx.com/supergen-submits-application-for-emea-approval-of-orathecin/ 2016-11-28T14:27:46+00:00 monthly 0.2 https://astx.com/supergen-announces-publication-of-phase-ii-studies-of-dacogen-in-advanced-mds-patients/ 2016-11-28T14:27:11+00:00 monthly 0.2 https://astx.com/supergen-reports-second-quarter-financial-results/ 2016-11-28T14:26:31+00:00 monthly 0.2 https://astx.com/mgi-pharma-and-supergen-announce-signing-of-a-worldwide-license-agreement-for-dacogen/ 2016-11-28T14:25:58+00:00 monthly 0.2 https://astx.com/mgi-pharma-and-supergen-announce-closing-of-stock-purchase-agreement-and-effectiveness-of-license-agreement/ 2016-11-28T14:25:25+00:00 monthly 0.2 https://astx.com/supergen-and-mgi-pharma-announce-submission-of-maa-for-approval-of-dacogen-in-europe/ 2016-11-28T14:24:53+00:00 monthly 0.2 https://astx.com/supergen-reports-third-quarter-financial-results/ 2016-11-28T14:24:21+00:00 monthly 0.2 https://astx.com/supergen-and-mgi-pharma-announce-acceptance-of-dacogen-maa-for-review-by-emea/ 2016-11-28T14:23:57+00:00 monthly 0.2 https://astx.com/supergen-and-mgi-pharma-announce-submission-of-dacogen-nda-to-u-s-fda/ 2016-11-28T14:23:11+00:00 monthly 0.2 https://astx.com/supergen-granted-fda-approval-of-paclitaxel-anda/ 2016-11-28T14:22:40+00:00 monthly 0.2 https://astx.com/williams-p-a-et-al-crystal-structures-of-human-cytochrome-p450-3a4-bound-to-metyrapone-and-progesterone-science-305-no-5684-2004-683-686-doi-10-1126science-1099736/ 2016-11-29T13:06:20+00:00 monthly 0.2 https://astx.com/verdonk-m-l-et-al-virtual-screening-using-protein%e2%88%92ligand-docking-avoiding-artificial-enrichment-journal-of-chemical-information-and-modeling-44-no-3-2004-793-806-doi-10/ 2016-11-29T13:05:48+00:00 monthly 0.2 https://astx.com/verdonk-m-l-hartshorn-m-j-structure-guided-fragment-screening-for-lead-discovery-current-opinion-in-drug-discovery-and-development-7-2004-404-410/ 2016-11-29T13:05:24+00:00 monthly 0.2 https://astx.com/tickle-i-et-al-high-throughput-protein-crystallography-and-drug-discovery-chemical-society-reviews-33-no-8-2004-558-565-doi-10-1039b314510g/ 2016-11-29T13:05:03+00:00 monthly 0.2 https://astx.com/rees-d-c-et-al-fragment-based-lead-discovery-nature-reviews-drug-discovery-3-2004-660-672-doi-10-1038nrd1467/ 2016-11-29T13:04:39+00:00 monthly 0.2 https://astx.com/patel-s-et-al-apo-and-inhibitor-complex-structures-of-bace-%ce%b2-secretase-journal-of-molecular-biology-343-no-2-2004-407-416-doi-10-1016j-jmb-2004-08-018/ 2016-11-29T13:04:09+00:00 monthly 0.2 https://astx.com/gill-a-l-new-lead-generation-strategies-for-protein-kinase-inhibitors-fragment-based-screening-approaches-mini-reviews-in-medicinal-chemistry-4-no-3-2004-301-311/ 2016-11-29T13:03:08+00:00 monthly 0.2 https://astx.com/supergen-announces-90-day-extension-of-fda-review-date-for-orathecin-new-drug-application/ 2016-11-28T14:21:15+00:00 monthly 0.2 https://astx.com/astex-chosen-by-the-world-economic-forum-as-a-technology-pioneer-for-2005/ 2021-05-07T11:27:02+00:00 monthly 0.2 https://astx.com/studies-exploring-nipent-in-combination-cancer-therapies-in-the-treatment-of-graft-versus-host-disease-gvhd-presented-at-american-society-of-hematology-annual-meeting/ 2016-11-28T14:42:59+00:00 monthly 0.2 https://astx.com/supergen-announces-withdrawal-of-orathecin-nda/ 2016-11-28T14:18:05+00:00 monthly 0.2 https://astx.com/dacogen-nda-accepted-for-filing-by-fda/ 2016-11-28T14:17:39+00:00 monthly 0.2 https://astx.com/dr-joseph-rubinfeld-resigns-from-supergens-board-of-directors/ 2016-11-28T14:17:05+00:00 monthly 0.2 https://astx.com/supergen-reports-2004-fourth-quarter-and-year-end-financial-results/ 2016-11-28T14:16:35+00:00 monthly 0.2 https://astx.com/supergen-initiates-phase-ii-combination-trial-of-orathecin-and-gemcitabine-in-chemotherapy-naive-pancreatic-cancer-patients/ 2016-11-28T14:15:13+00:00 monthly 0.2 https://astx.com/supergen-appoints-allan-r-goldberg-ph-d-to-board-of-directors/ 2016-11-28T14:14:44+00:00 monthly 0.2 https://astx.com/supergen-reports-2005-first-quarter-financial-results/ 2016-11-28T14:14:11+00:00 monthly 0.2 https://astx.com/supergen-reports-results-of-phase-iii-rescue-study-with-orathecin-rubitecan-capsules-versus-5-fu-in-pancreatic-cancer-patients/ 2016-11-28T14:13:41+00:00 monthly 0.2 https://astx.com/astex-announces-clinical-trial-authorization-for-novel-cancer-drug-at7519-and-plans-for-two-further-new-drug-filings-in-the-next-nine-months/ 2016-11-28T14:13:05+00:00 monthly 0.2 https://astx.com/astex-announces-ind-approval-for-novel-cancer-drug-at7519/ 2016-11-28T14:12:42+00:00 monthly 0.2 https://astx.com/supergen-reports-2005-second-quarter-financial-results/ 2016-11-28T14:12:00+00:00 monthly 0.2 https://astx.com/astrazeneca-and-astex-announce-new-anti-cancer-drug-discovery-alliance/ 2016-11-28T14:11:22+00:00 monthly 0.2 https://astx.com/approvable-letter-received-from-the-fda-for-dacogen-decitabine-injection-for-the-treatment-of-mds/ 2016-11-28T14:10:49+00:00 monthly 0.2 https://astx.com/supergen-reports-2005-third-quarter-financial-results/ 2016-11-28T14:10:17+00:00 monthly 0.2 https://astx.com/mgi-pharma-and-supergen-provide-regulatory-status-updates-for-dacogen-decitabine-injection-for-mds/ 2016-11-28T14:09:43+00:00 monthly 0.2 https://astx.com/thompson-n-lyons-j-recent-progress-in-targeting-the-rafmekerk-pathway-with-inhibitors-in-cancer-drug-discovery-current-opinion-in-pharmacology-5-no-4-2005-350-356-doi-10-1016j/ 2016-11-29T13:01:53+00:00 monthly 0.2 https://astx.com/robin-a-e-carr-miles-congreve-christopher-w-murray-david-c-rees-fragment-based-lead-discovery-leads-by-design-drug-discovery-today-10-no-14-2005-987-992-doi-10-1016s1359-644/ 2016-11-29T13:01:30+00:00 monthly 0.2 https://astx.com/miles-congreve-christopher-w-murray-and-tom-l-blundell-keynote-review-structural-biology-and-drug-discovery-drug-discovery-today-10-no-13-2005-895-907-doi-10-1016s1359-644605/ 2016-11-29T13:01:04+00:00 monthly 0.2 https://astx.com/kirton-s-b-et-al-prediction-of-binding-modes-for-ligands-in-the-cytochromes-p450-and-other-heme-containing-proteins-proteins-structure-function-and-bioinformatics-58-no-4-2005-836/ 2016-11-29T13:00:25+00:00 monthly 0.2 https://astx.com/hartshorn-m-j-et-al-fragment-based-lead-discovery-using-x-ray-crystallography-journal-of-medicinal-chemistry-48-no-2-2005-403-413-doi-10-1021jm0495778/ 2016-11-29T12:59:35+00:00 monthly 0.2 https://astx.com/gill-a-l-et-al-identification-of-novel-p38%ce%b1-map-kinase-inhibitors-using-fragment-based-lead-generation-journal-of-medicinal-chemistry-48-no-2-2005-414-426-doi-10-1021jm0495/ 2016-11-29T12:59:12+00:00 monthly 0.2 https://astx.com/gill-a-et-al-the-discovery-of-novel-protein-kinase-inhibitors-by-using-fragment-based-high-throughput-x-ray-crystallography-chembiochem-6-no-3-2005-506-512-doi-10-1002cbic-20040/ 2016-11-29T12:58:51+00:00 monthly 0.2 https://astx.com/astex-announces-new-licensing-and-drug-discovery-alliance-to-develop-novel-cell-cycle-cancer-drugs/ 2016-11-28T14:09:09+00:00 monthly 0.2 https://astx.com/studies-of-nipent-in-combination-cancer-therapies-for-treatment-of-chronic-lymphocytic-leukemia-and-graft-versus-host-disease-gvhd-presented-at-american-society-of-hematology-annual-meeting/ 2016-11-28T14:08:40+00:00 monthly 0.2 https://astx.com/dacogen-decitabine-injection-data-presented-at-american-society-of-hematology-ash-annual-meeting/ 2016-11-28T14:08:03+00:00 monthly 0.2 https://astx.com/dacogen-decitabine-injection-complete-response-accepted-for-review-by-u-s-fda/ 2016-11-28T14:07:31+00:00 monthly 0.2 https://astx.com/supergen-announces-withdrawal-of-orathecin-marketing-authorization-application/ 2016-11-28T14:04:18+00:00 monthly 0.2 https://astx.com/supergen-announces-signing-of-definitive-agreement-to-acquire-montigen-pharmaceuticals/ 2016-11-28T14:03:27+00:00 monthly 0.2 https://astx.com/supergen-reports-2005-fourth-quarter-and-year-end-financial-results/ 2016-11-28T14:02:58+00:00 monthly 0.2 https://astx.com/astex-announces-new-drug-discovery-collaboration-with-university-of-newcastle-upon-tyne-and-cancer-research-technology-limited/ 2016-11-28T14:02:25+00:00 monthly 0.2 https://astx.com/supergen-announces-results-from-combination-study-in-cll-published-in-the-journal-of-clinical-oncology/ 2016-11-28T14:01:49+00:00 monthly 0.2 https://astx.com/supergen-completes-acquisition-of-montigen-pharmaceuticals/ 2016-11-28T14:01:16+00:00 monthly 0.2 https://astx.com/supergen-reports-2006-first-quarter-financial-results/ 2016-11-28T14:00:43+00:00 monthly 0.2 https://astx.com/astex-therapeutics-announces-ind-approval-for-novel-cancer-drug-at9283/ 2016-11-28T14:00:12+00:00 monthly 0.2 https://astx.com/supergen-announces-interim-results-of-orathecin-combination-trial-in-pancreatic-cancer/ 2016-11-28T13:59:42+00:00 monthly 0.2 https://astx.com/u-s-fda-approves-dacogen-decitabine-for-injection/ 2016-11-28T13:59:09+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-analyst-investor-day/ 2016-11-28T13:58:33+00:00 monthly 0.2 https://astx.com/supergen-announces-achievement-of-20-million-dacogen-decitabine-injection-milestone/ 2016-11-28T13:57:57+00:00 monthly 0.2 https://astx.com/supergen-receives-u-s-patent-for-nipent-pentostatin-for-injection/ 2016-11-28T13:57:22+00:00 monthly 0.2 https://astx.com/supergen-completes-contract-to-transition-wyeth-distribution-of-nipent-outside-of-the-u-s/ 2016-11-28T13:56:48+00:00 monthly 0.2 https://astx.com/mayne-acquires-supergens-north-american-oncology-products/ 2016-11-28T13:56:10+00:00 monthly 0.2 https://astx.com/supergen-announces-attainment-of-milestone-from-the-mgi-pharma-cilag-gmbh-a-johnson-johnson-company-licensing-for-dacogentm-decitabine-for-injection/ 2016-11-28T13:55:40+00:00 monthly 0.2 https://astx.com/supergen-reports-2006-second-quarter-financial-results/ 2016-11-28T13:54:21+00:00 monthly 0.2 https://astx.com/new-anti-cancer-drug-discovery-alliance-between-glaxosmithkline-the-wellcome-trust-and-the-institute-of-cancer-research-focused-on-b-raf-inhibitors-builds-on-partnership-between-astex-the-wellcome/ 2016-11-28T13:55:06+00:00 monthly 0.2 https://astx.com/mayne-pharmas-purchase-of-supergens-north-american-oncology-products-completes/ 2016-11-28T13:53:48+00:00 monthly 0.2 https://astx.com/astex-therapeutics-initiates-clinical-trial-with-investigational-anti-cancer-drug-at9283/ 2016-11-28T13:53:24+00:00 monthly 0.2 https://astx.com/supergen-coo-to-leave-company-at-year-end/ 2016-11-28T13:52:45+00:00 monthly 0.2 https://astx.com/supergen-reports-2006-third-quarter-financial-results/ 2016-11-28T13:52:07+00:00 monthly 0.2 https://astx.com/supergen-presents-preclinical-data-at-eortc-on-mp-529-a-selective-kinase-inhibitor-and-climb-process-in-drug-discovery-and-design/ 2016-11-28T13:51:41+00:00 monthly 0.2 https://astx.com/supergen-presents-preclinical-data-on-selected-lead-kinase-compounds-and-dna-methylation-inhibitor-at-eortc/ 2016-11-28T13:51:11+00:00 monthly 0.2 https://astx.com/2006-aacr-eortc_at7519-pd-biomarker-activity-in-phase-1-study/ 2016-11-25T14:13:33+00:00 monthly 0.2 https://astx.com/mayne-pharma-acquires-remaining-nipent-rights/ 2016-11-28T13:50:41+00:00 monthly 0.2 https://astx.com/murray-c-w-verdonk-et-al-entropic-consequences-of-linking-ligands-fragment-based-approaches-in-drug-discovery-volume-34-chapter-3-pp-55-66-edited-by-w-jahnke-and-d-a-erlanson-wiley-vcg/ 2016-11-29T12:57:39+00:00 monthly 0.2 https://astx.com/mooij-w-t-m-et-al-automated-protein-ligand-crystallography-for-structure-based-drug-design-chemmedchem-1-no-8-2006-827-838-doi-10-1002cmdc-200600074/ 2016-11-29T12:57:16+00:00 monthly 0.2 https://astx.com/howard-n-et-al-application-of-fragment-screening-and-fragment-linking-to-the-discovery-of-novel-thrombin-inhibitors-journal-of-medicinal-chemistry-49-no-4-2006-1346-1355-doi-10-1/ 2016-11-29T12:56:55+00:00 monthly 0.2 https://astx.com/davies-thomas-g-et-al-pyramid-an-integrated-platform-for-fragment-based-drug-discovery-fragment-based-approaches-in-drug-discovery-volume-34-chapter-10-pp-193-214-edited-by-w-jahnke-and-d/ 2016-11-29T12:56:35+00:00 monthly 0.2 https://astx.com/astex-therapeutics-appoints-john-aston-chief-financial-officer/ 2016-11-28T13:50:11+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-march-2-analysts-and-investor-day/ 2016-11-28T13:49:16+00:00 monthly 0.2 https://astx.com/supergen-to-release-2006-fourth-quarter-and-year-end-financial-results-march-14/ 2016-11-28T13:48:53+00:00 monthly 0.2 https://astx.com/supergen-to-present-discovery-platform-and-pipeline-update-at-analyst-and-investor-day/ 2016-11-28T13:48:31+00:00 monthly 0.2 https://astx.com/supergen-reports-2006-fourth-quarter-and-year-end-financial-results/ 2016-11-28T13:48:03+00:00 monthly 0.2 https://astx.com/nipent-acquisition-by-hospira-is-complete/ 2016-11-28T13:47:39+00:00 monthly 0.2 https://astx.com/supergen-to-highlight-oncology-pipeline-data-in-multiple-presentations-at-aacr/ 2016-11-28T13:47:13+00:00 monthly 0.2 https://astx.com/data-show-supergens-multi-targeted-tyrosine-kinase-inhibitor-suppresses-critical-double-stranded-dna-repair-protein-rad51/ 2016-11-28T13:46:51+00:00 monthly 0.2 https://astx.com/supergen-sells-select-non-core-assets-to-intas/ 2016-11-28T13:46:24+00:00 monthly 0.2 https://astx.com/2007_comparison-of-at7519-in-solid-tumor-and-hematological-cell-lines/ 2016-11-25T14:13:06+00:00 monthly 0.2 https://astx.com/supergen-receives-fda-clearance-to-initiate-phase-i-clinical-trial-with-mp470/ 2016-11-28T13:46:00+00:00 monthly 0.2 https://astx.com/supergen-to-release-2007-first-quarter-financial-results-may-2/ 2016-11-28T13:45:35+00:00 monthly 0.2 https://astx.com/supergen-reports-2007-first-quarter-financial-results/ 2016-11-28T13:45:09+00:00 monthly 0.2 https://astx.com/supergen-to-participate-in-brean-murray-carret-co-healthcare-biotechnology-small-cap-one-on-one-conference/ 2016-11-28T13:44:43+00:00 monthly 0.2 https://astx.com/supergen-names-gregory-berk-m-d-chief-medical-officer/ 2016-11-28T13:44:14+00:00 monthly 0.2 https://astx.com/supergen-announces-first-meeting-of-newly-formed-scientific-advisory-board/ 2016-11-28T13:43:50+00:00 monthly 0.2 https://astx.com/supergen-reports-dosing-of-first-patient-in-phase-i-trial-of-novel-tyrosine-kinase-inhibitor/ 2016-11-28T13:43:25+00:00 monthly 0.2 https://astx.com/2007-ash_at7519-is-active-in-leukemia-models-and-primary-cll-patient-samples/ 2016-11-25T14:12:32+00:00 monthly 0.2 https://astx.com/supergen-reports-2007-second-quarter-financial-results/ 2016-11-28T13:42:59+00:00 monthly 0.2 https://astx.com/dr-audrey-f-jakubowski-of-supergen-retires-as-chief-regulatory-and-quality-officer/ 2016-11-28T13:42:33+00:00 monthly 0.2 https://astx.com/supergen-to-highlight-oncology-pipeline-data-in-multiple-presentations-at-the-aacr-nci-eortc-international-conference/ 2016-11-28T13:40:57+00:00 monthly 0.2 https://astx.com/astex-drug-candidates-to-be-featured-at-the-2007-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2016-11-28T13:40:33+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-investigatoranalyst-pipeline-update-presentation-october-24/ 2016-11-28T13:40:03+00:00 monthly 0.2 https://astx.com/supergens-novel-hypomethylating-agent-highlighted-at-aacr-plenary-session/ 2016-11-28T13:39:43+00:00 monthly 0.2 https://astx.com/data-show-supergens-multi-targeted-tyrosine-kinase-inhibitor-demonstrates-synergy-with-dna-damaging-agents/ 2016-11-28T13:39:21+00:00 monthly 0.2 https://astx.com/data-support-use-of-supergens-climb-technology-in-lead-development-and-optimization/ 2016-11-28T13:39:00+00:00 monthly 0.2 https://astx.com/supergen-reports-2007-third-quarter-financial-results/ 2016-11-28T13:37:51+00:00 monthly 0.2 https://astx.com/data-show-supergens-multi-targeted-tyrosine-kinase-inhibitor-demonstrates-pre-clinical-activity-in-glioblastoma-multiforme/ 2016-11-28T13:37:31+00:00 monthly 0.2 https://astx.com/2007-gordon-fragment-based-drug-design-of-at13387-a-novel-and-efficacious-hsp90-inhibitor/ 2016-11-25T15:30:48+00:00 monthly 0.2 https://astx.com/saxty-et-al-identification-of-inhibitors-of-protein-kinase-b-using-fragment-based-lead-discovery-journal-of-medicinal-chemistry-50-no-10-2007-2293-2296-doi-10-1021jm070091b/ 2016-11-29T12:52:47+00:00 monthly 0.2 https://astx.com/p-day-et-al-structure-of-a-cbs-domain-pair-from-the-regulatory-%ce%b31-subunit-of-human-ampk-in-complex-with-amp-and-zmp-acta-crystallographica-d63-2007-587-596-doi-10-1107s090744490700911/ 2016-11-29T12:52:25+00:00 monthly 0.2 https://astx.com/miles-congreve-et-al-application-of-fragment-screening-by-x-ray-crystallography-to-the-discovery-of-aminopyridines-as-inhibitors-of-%ce%b2-secretase-journal-of-medicinal-chemistry-50-no-6-2007/ 2016-11-29T12:52:04+00:00 monthly 0.2 https://astx.com/michael-j-hartshorn-et-al-diverse-high-quality-test-set-for-the-validation-of-protein%e2%88%92ligand-docking-performance-journal-of-medicinal-chemistry-50-no-4-2007-726-741-doi-1/ 2016-11-29T12:51:40+00:00 monthly 0.2 https://astx.com/jhoti-harren-leach-andrew-eds-structure-based-drug-discovery-springer-xii-252p-hardcover-2007-isbn-978-1-4020-4406-9/ 2016-11-29T12:51:19+00:00 monthly 0.2 https://astx.com/christopher-w-murray-et-al-application-of-fragment-screening-by-x-ray-crystallography-to-%ce%b2-secretase-journal-of-medicinal-chemistry-50-no-6-2007-1116-1123-doi-10-1021jm061196/ 2016-11-29T12:50:57+00:00 monthly 0.2 https://astx.com/astex-drug-candidates-to-be-presented-at-the-2007-american-society-of-hematology-annual-meeting/ 2016-11-28T13:37:11+00:00 monthly 0.2 https://astx.com/supergen-to-highlight-oncology-pipeline-data-in-multiple-presentations-at-the-american-society-of-hematologys-49th-annual-meeting/ 2016-11-28T13:36:48+00:00 monthly 0.2 https://astx.com/data-indicate-that-supergens-lead-jak2-kinase-inhibitors-prevent-cancer-cell-proliferation-in-non-clinical-models/ 2016-11-28T13:36:23+00:00 monthly 0.2 https://astx.com/supergens-climb-technology-identifies-lead-pim-kinase-inhibitors/ 2016-11-28T13:36:00+00:00 monthly 0.2 https://astx.com/supergens-novel-hypomethylating-agent-highlighted-at-american-society-of-hematology-annual-meeting/ 2016-11-28T13:35:36+00:00 monthly 0.2 https://astx.com/supergen-reports-initiation-of-multi-arm-phase-1b-trial-of-novel-tyrosine-kinase-inhibitor/ 2016-11-28T13:35:12+00:00 monthly 0.2 https://astx.com/astex-receives-ind-approval-for-its-small-molecule-hsp90-inhibitor-at13387-astex-announces-extension-of-drug-discovery-alliance/ 2016-11-28T13:06:29+00:00 monthly 0.2 https://astx.com/supergen-reports-2007-fourth-quarter-and-annual-financial-results/ 2016-11-28T13:06:01+00:00 monthly 0.2 https://astx.com/supergens-dna-methyltransferase-inhibitor-s-110-improves-in-vivo-efficacy-profile-of-decitabine/ 2016-11-28T13:05:27+00:00 monthly 0.2 https://astx.com/supergen-to-highlight-oncology-pipeline-data-in-multiple-presentations-at-the-aacr-annual-meeting-2/ 2016-11-28T13:04:55+00:00 monthly 0.2 https://astx.com/astex-drug-candidates-to-be-presented-at-the-2008-aacr-annual-meeting/ 2016-11-28T13:04:22+00:00 monthly 0.2 https://astx.com/supergens-mp-470-sensitizes-prostate-and-breast-cancer-cells-to-erlotinib/ 2016-11-28T13:03:49+00:00 monthly 0.2 https://astx.com/data-show-supergens-mp-470-is-safe-in-humans/ 2016-11-28T13:03:16+00:00 monthly 0.2 https://astx.com/supergen-identifies-lead-pim-kinase-inhibitor-sgi-1776-that-causes-tumor-regression-in-aml-xenograft-models/ 2016-11-28T13:02:44+00:00 monthly 0.2 https://astx.com/royal-society-of-chemistry-recognises-astex-scientists/ 2016-11-28T13:02:09+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-3rd-annual-analyst-day-on-april-29-2008/ 2016-11-28T13:01:33+00:00 monthly 0.2 https://astx.com/supergen-reports-2008-first-quarter-financial-results/ 2016-11-28T13:01:04+00:00 monthly 0.2 https://astx.com/2008-ash_at7519-is-active-in-cll-patient-samples-independent-of-stage/ 2016-11-25T14:11:07+00:00 monthly 0.2 https://astx.com/astex-drug-candidates-to-be-presented-at-the-2008-american-society-of-clinical-oncology-annual-meeting/ 2016-11-28T13:00:29+00:00 monthly 0.2 https://astx.com/astex-announces-new-drug-discovery-alliance-with-janssen-pharmaceutica-n-v/ 2016-11-28T12:59:55+00:00 monthly 0.2 https://astx.com/supergens-pim-kinase-inhibitor-sgi-1776-causes-tumor-regression-in-aml-xenograft-models/ 2016-11-28T12:59:20+00:00 monthly 0.2 https://astx.com/supergens-jak2-inhibitor-sgi-1252-inhibits-in-vivo-tumor-cell-proliferation/ 2016-11-28T12:58:48+00:00 monthly 0.2 https://astx.com/supergen-comments-on-preliminary-efficacy-update-on-eortc-phase-3-trial-of-dacogen-versus-supportive-care-in-patients-with-myelodysplastic-syndromes/ 2016-11-28T12:58:17+00:00 monthly 0.2 https://astx.com/supergen-reports-2008-second-quarter-financial-results/ 2016-11-28T12:57:47+00:00 monthly 0.2 https://astx.com/supergen-granted-orphan-drug-designation-for-mp-470-in-glioblastoma-multiforme/ 2016-11-28T12:57:13+00:00 monthly 0.2 https://astx.com/2008_a-dose-escalation-pk-and-pd-study-of-at7519-in-patients-with-refractory-solid-tumors/ 2016-11-25T14:10:36+00:00 monthly 0.2 https://astx.com/cancer-research-uk-and-astex-therapeutics-join-forces-to-develop-new-anti-cancer-treatment/ 2016-11-28T12:56:42+00:00 monthly 0.2 https://astx.com/supergen-to-present-data-at-eortc-nci-aacr/ 2016-11-28T12:56:10+00:00 monthly 0.2 https://astx.com/supergens-mp-470-demonstrates-clinical-tumor-regression-when-combined-with-standard-of-care-chemotherapy/ 2016-11-28T12:55:40+00:00 monthly 0.2 https://astx.com/supergen-reports-2008-third-quarter-financial-results/ 2016-11-28T12:55:09+00:00 monthly 0.2 https://astx.com/2008-eortc_in-vivo-activity-of-sgi-110-a-novel-hypomethylating-agent-2/ 2016-11-25T16:45:04+00:00 monthly 0.2 https://astx.com/supergen-receives-clearance-to-begin-clinical-trials-with-sgi-1776-a-pim-inhibitor/ 2016-11-28T12:53:41+00:00 monthly 0.2 https://astx.com/2008-eortc_in-vivo-activity-of-sgi-110-a-novel-hypomethylating-agent/ 2016-12-01T12:33:47+00:00 monthly 0.2 https://astx.com/2008-ash_anti-aml-activity-of-sgi-110-and-sgi-1036-panobinostat-combined-therapy/ 2016-12-01T12:33:03+00:00 monthly 0.2 https://astx.com/2008-ash_anti-aml-activity-of-sgi-110-and-sgi-1036-panobinostat-combined-therapy-2/ 2016-11-25T16:44:39+00:00 monthly 0.2 https://astx.com/verdonk-et-al-protein%e2%88%92ligand-docking-against-non-native-protein-conformers-journal-of-chemical-information-and-modeling-48-no-11-2008-2214-2225-doi-10-1021ci8002254/ 2016-11-29T12:49:40+00:00 monthly 0.2 https://astx.com/paul-g-wyatt-andrew-j-woodhead-valerio-berdini-et-al-identification-of-n-4-piperidinyl-4-26-dichlorobenzoylamino-1h-pyrazole-3-carboxamide-at7519-a-novel-cyclin-dependent-kinase-inhibit/ 2016-11-29T12:49:18+00:00 monthly 0.2 https://astx.com/miles-congreve-et-al-recent-developments-in-fragment-based-drug-discovery-journal-of-medicinal-chemistry-51-no-13-2008-3661-3680-doi-10-1021jm8000373/ 2016-11-29T12:48:56+00:00 monthly 0.2 https://astx.com/marcel%e2%80%85l-verdonk-and-david%e2%80%85c-rees-group-efficiency-a-guideline-for-hits-to-leads-chemistry-chemmedchem-3-no-8-2008-1179-1180-doi-10-1002cmdc-200800132/ 2016-11-29T12:48:25+00:00 monthly 0.2 https://astx.com/frederickson-et-al-fragment-based-discovery-of-mexiletine-derivatives-as-orally-bioavailable-inhibitors-of-urokinase-type-plasminogen-activator-journal-of-medicinal-chemistry-51-no-2-2008-183/ 2016-11-29T12:48:01+00:00 monthly 0.2 https://astx.com/astex-presents-updates-on-at7519-and-at9283-at-the-american-society-of-hematology-ash-conference/ 2016-11-28T12:52:57+00:00 monthly 0.2 https://astx.com/supergen-to-present-data-at-the-50th-ash-annual-meeting-exposition/ 2016-11-28T12:52:25+00:00 monthly 0.2 https://astx.com/supergens-pim-kinase-inhibitor-sgi-1776-effective-in-pre-clinical-models-of-acute-lymphoblastic-leukemia/ 2016-11-28T12:51:50+00:00 monthly 0.2 https://astx.com/astex-and-cancer-research-uk-collaborate-on-clinical-studies-of-at9283-in-childhood-cancers/ 2016-11-28T12:49:23+00:00 monthly 0.2 https://astx.com/astex-scientists-solve-structure-of-cyclin-dependent-kinase-4/ 2016-11-28T12:48:45+00:00 monthly 0.2 https://astx.com/astex-receives-award-from-the-multiple-myeloma-research-foundation-to-support-clinical-development-of-at7519/ 2016-11-28T12:48:13+00:00 monthly 0.2 https://astx.com/supergen-reports-2008-fourth-quarter-and-year-end-financial-results/ 2016-11-28T12:47:31+00:00 monthly 0.2 https://astx.com/astex-awarded-2-million-from-wellcome-trust-for-pioneering-hcv-research/ 2016-11-28T12:46:58+00:00 monthly 0.2 https://astx.com/astex-achieves-milestones-in-drug-discovery-collaboration/ 2016-11-28T12:46:24+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-4th-annual-analyst-day-on-april-14-2009/ 2016-11-28T12:45:23+00:00 monthly 0.2 https://astx.com/supergen-to-highlight-oncology-pipeline-data-in-multiple-presentations-at-the-aacr-annual-meeting/ 2016-11-28T12:44:26+00:00 monthly 0.2 https://astx.com/astex-reports-positive-clinical-biomarker-data-from-its-phase-i-study-on-cdk-inhibitor-at7519-at-the-aacr-annual-meeting-2009/ 2016-11-28T12:43:51+00:00 monthly 0.2 https://astx.com/supergen-presents-pim-kinase-inhibitor-sgi-1776-at-american-association-for-cancer-research-annual-meeting/ 2016-11-28T12:43:17+00:00 monthly 0.2 https://astx.com/supergen-identifies-new-class-of-etkbmx-kinase-inhibitors/ 2016-11-28T12:42:40+00:00 monthly 0.2 https://astx.com/supergen-reports-2009-first-quarter-financial-results/ 2016-11-28T12:42:08+00:00 monthly 0.2 https://astx.com/supergen-announces-departure-of-chief-medical-officer/ 2016-11-28T12:41:40+00:00 monthly 0.2 https://astx.com/supergens-mp-470-demonstrates-clinical-benefit-in-lung-cancer-patients/ 2016-11-28T12:40:38+00:00 monthly 0.2 https://astx.com/astex-reports-positive-data-from-its-phase-i-study-of-at9283-at-the-asco-annual-meeting-2009/ 2016-11-28T12:40:02+00:00 monthly 0.2 https://astx.com/supergen-names-mohammad-azab-m-d-chief-medical-officer/ 2016-11-28T12:39:29+00:00 monthly 0.2 https://astx.com/supergen-reports-2009-second-quarter-financial-results/ 2016-11-28T12:38:56+00:00 monthly 0.2 https://astx.com/supergens-mp-470-demonstrates-clinical-benefit-in-small-cell-lung-cancer-and-neuroendocrine-tumor-patients/ 2016-11-28T12:38:15+00:00 monthly 0.2 https://astx.com/david-bearss-resigns-as-chief-scientific-officer-to-join-huntsman-cancer-institute-as-co-director-of-center-for-investigational-therapeutics/ 2016-11-28T12:37:35+00:00 monthly 0.2 https://astx.com/supergen-and-gsk-to-collaborate-on-the-discovery-and-development-of-novel-epigenetic-therapeutics/ 2016-11-28T12:36:57+00:00 monthly 0.2 https://astx.com/supergen-reports-2009-third-quarter-financial-results/ 2016-11-28T12:36:22+00:00 monthly 0.2 https://astx.com/astex-announces-a-crada-with-the-national-cancer-institute-for-its-hsp90-inhibitor-at13387/ 2016-11-28T12:35:51+00:00 monthly 0.2 https://astx.com/astex-to-disclose-the-structure-of-its-hsp90-inhibitor-at13387-at-the-aacr-nci-eortc-annual-meeting-2009/ 2016-11-28T12:35:06+00:00 monthly 0.2 https://astx.com/supergen-presentations-at-aacr-nci-eortc/ 2016-11-28T12:34:38+00:00 monthly 0.2 https://astx.com/astex-announces-strategic-drug-discovery-alliance-with-glaxosmithkline/ 2016-11-28T12:33:49+00:00 monthly 0.2 https://astx.com/supergen-appoints-david-bearss-ph-d-chief-scientific-officer/ 2016-11-28T12:54:33+00:00 monthly 0.2 https://astx.com/astex-granted-orphan-drug-status-for-at9283-in-aml-in-usa-and-europe/ 2016-11-28T12:33:21+00:00 monthly 0.2 https://astx.com/2009-aacr-id-of-predicted-biologically-effective-dose-of-at7519-in-phase-1-study/ 2016-11-25T14:09:47+00:00 monthly 0.2 https://astx.com/2009-eortc-fragment-based-drug-discovery-of-hsp90-inhibitor-at13387/ 2016-11-25T15:30:24+00:00 monthly 0.2 https://astx.com/howard-et-al-fragment-based-discovery-of-the-pyrazol-4-yl-urea-at9283-a-multi-targeted-kinase-inhibitor-with-potent-aurora-kinase-activity-journal-of-medicinal-chemistry-52-no-2-2009-379/ 2016-11-29T12:29:06+00:00 monthly 0.2 https://astx.com/day-et-al-crystal-structure-of-human-cdk4-in-complex-with-a-d-type-cyclin-proceedings-of-the-national-academy-of-sciences-106-no-11-2009-4166-4170-doi-10-1073pnas-0809645106/ 2016-11-29T12:29:49+00:00 monthly 0.2 https://astx.com/davies-et-al-fragment-based-discovery-of-inhibitors-of-protein-kinase-b-current-topics-in-medicinal-chemistry-9-no-18-2009-1705-1717/ 2016-11-29T12:29:46+00:00 monthly 0.2 https://astx.com/curry-j-et-al-aurora-kinase-inhibition-in-mitosis-strategies-for-optimising-the-use-of-aurora-kinase-inhibitors-such-as-at9283-cell-cycle-8-no-12-2009-1-9-doi-10-4161cc-8-12-8741/ 2016-11-29T12:29:41+00:00 monthly 0.2 https://astx.com/christopher-w-murray-and-david-c-rees-the-rise-of-fragment-based-drug-discovery-nature-chemistry-1-no-3-2009-187-192-doi-10-1038nchem-217/ 2016-11-29T12:29:38+00:00 monthly 0.2 https://astx.com/supergen-data-presentations-at-american-society-of-hematology-ash-annual-meeting/ 2016-11-28T12:32:46+00:00 monthly 0.2 https://astx.com/astex-wins-company-newsflow-of-the-year-award/ 2016-11-28T12:32:01+00:00 monthly 0.2 https://astx.com/clinical-candidate-from-pkbakt-collaboration-with-astex-selected-by-astrazeneca/ 2016-11-28T12:28:22+00:00 monthly 0.2 https://astx.com/astex-executive-receives-the-astrazeneca-business-development-professional-of-the-year-2009-award/ 2016-11-28T12:27:51+00:00 monthly 0.2 https://astx.com/2010-isbtc_immunomodulatory-activity-of-sgi-110/ 2016-12-01T12:36:14+00:00 monthly 0.2 https://astx.com/supergen-reports-2009-fourth-quarter-and-year-end-financial-results/ 2016-11-28T12:27:22+00:00 monthly 0.2 https://astx.com/encouraging-data-from-three-astex-collaborative-programmes-to-be-presented-at-the-101st-american-association-for-cancer-research-aacr-annual-meeting-2010/ 2016-11-28T12:26:48+00:00 monthly 0.2 https://astx.com/supergen-reports-2010-first-quarter-financial-results/ 2016-11-28T12:26:13+00:00 monthly 0.2 https://astx.com/encouraging-interim-data-from-a-phase-i-study-of-astexs-hsp90-inhibitor-at13387-to-be-presented-at-asco/ 2016-11-28T12:25:39+00:00 monthly 0.2 https://astx.com/2010-eortc_immunomodulatory-activity-of-sgi-110/ 2016-12-01T12:35:50+00:00 monthly 0.2 https://astx.com/dacogen-decitabine-for-injection-phase-iii-aml-results-announced/ 2016-11-28T12:24:57+00:00 monthly 0.2 https://astx.com/2010-ash_sgi-110-preclinical-pk-dna-methylation-of-low-vol-subcutaneous-formulation/ 2016-12-01T12:35:34+00:00 monthly 0.2 https://astx.com/astex-scientists-describe-novel-hsp90-inhibitors-in-two-key-publications-in-journal-of-medicinal-chemistry/ 2016-11-28T12:24:19+00:00 monthly 0.2 https://astx.com/supergen-reports-2010-second-quarter-financial-results/ 2016-11-28T12:23:44+00:00 monthly 0.2 https://astx.com/astex-and-multiple-myeloma-research-consortium-mmrc-announce-start-of-phase-ii-clinical-study-of-at7519-in-multiple-myeloma-2/ 2016-11-28T12:28:49+00:00 monthly 0.2 https://astx.com/2010-esh-novel-antagonists-of-xiap-ciap12-generated-by-fragment-based-drug-discovery/ 2016-11-25T14:36:58+00:00 monthly 0.2 https://astx.com/astex-and-multiple-myeloma-research-consortium-mmrc-announce-start-of-phase-ii-clinical-study-of-at7519-in-multiple-myeloma/ 2016-11-28T12:22:27+00:00 monthly 0.2 https://astx.com/milestone-transition-in-astex-alzheimers-disease-collaboration-with-astrazeneca/ 2016-11-28T12:21:46+00:00 monthly 0.2 https://astx.com/supergen-reports-2010-third-quarter-financial-results/ 2016-11-28T12:29:40+00:00 monthly 0.2 https://astx.com/2010-aacr-j_s110-is-effective-dna-methylation-inhibitor-in-vivo-and-reduces-tumor-growth/ 2016-12-01T12:35:17+00:00 monthly 0.2 https://astx.com/astex-and-the-ncic-clinical-trials-group-announce-start-of-phase-ii-clinical-study-of-at9283-in-multiple-myeloma/ 2016-11-28T12:20:18+00:00 monthly 0.2 https://astx.com/2010-isbtc_immunomodulatory-activity-of-sgi-110-2/ 2016-11-25T16:44:14+00:00 monthly 0.2 https://astx.com/supergen-discontinues-clinical-development-of-sgi-1776/ 2016-11-28T12:17:50+00:00 monthly 0.2 https://astx.com/2010-eortc_immunomodulatory-activity-of-sgi-110-2/ 2016-11-25T16:43:46+00:00 monthly 0.2 https://astx.com/encouraging-data-from-phase-i-studies-of-astexs-anti-cancer-drugs-at7519-at9283-and-at13387-to-be-presented-at-eortc-nci-aacr-annual-meeting/ 2016-11-24T16:19:29+00:00 monthly 0.2 https://astx.com/supergen-pipeline-presentations-at-eortc-nci-aacr/ 2016-11-24T16:17:06+00:00 monthly 0.2 https://astx.com/2010-ash_sgi-110-preclinical-pk-dna-methylation-of-low-vol-subcutaneous-formulation-2/ 2016-11-25T16:43:22+00:00 monthly 0.2 https://astx.com/2010-aacr-j_s110-is-effective-dna-methylation-inhibitor-in-vivo-and-reduces-tumor-growth-2/ 2016-11-25T16:42:52+00:00 monthly 0.2 https://astx.com/2010-eortc-novel-antagonists-of-xiap-ciap12-generated-by-fragment-based-drug-discovery/ 2016-11-25T14:36:32+00:00 monthly 0.2 https://astx.com/2010-asco-hsp90-inhibitor-in-refractory-solid-tumors-phase-i-study-of-at13387/ 2016-11-25T15:29:43+00:00 monthly 0.2 https://astx.com/2010-aacr_immunomodulatory-activity-of-sgi-110/ 2016-12-01T12:35:02+00:00 monthly 0.2 https://astx.com/2010-aacr_immunomodulatory-activity-of-sgi-110-2/ 2016-11-25T16:42:25+00:00 monthly 0.2 https://astx.com/woodhead-et-al-discovery-of-24-dihydroxy-5-isopropylphenyl-5-4-methylpiperazin-1-ylmethyl-13-dihydroisoindol-2-ylmethanone-at13387-a-novel-inhibitor-of-the-molecular-chaperone-hsp90-by-f/ 2016-11-29T12:23:41+00:00 monthly 0.2 https://astx.com/tanaka-et-al-activity-of-the-multi-targeted-kinase-inhibitor-at9283-in-imatinib-resistant-bcr-abl-positive-leukemic-cells-blood-116-no-12-2010-2089-2095-doi-10-1182blood-2009-03-211466/ 2016-11-29T12:23:17+00:00 monthly 0.2 https://astx.com/squires-m-et-al-at7519-a-cyclin-dependent-kinase-inhibitor-exerts-its-effects-by-transcriptional-inhibition-in-leukemia-cell-lines-and-patient-samples-molecular-cancer-therapeutics-9-no-4-2/ 2016-11-29T12:22:54+00:00 monthly 0.2 https://astx.com/santo-et-al-at7519-a-novel-small-molecule-multi-cyclin-dependent-kinase-inhibitor-induces-apoptosis-in-multiple-myeloma-via-gsk-3beta-activation-and-rna-polymerase-ii-inhibition-oncogene-29-n/ 2016-11-29T12:22:24+00:00 monthly 0.2 https://astx.com/murray-et-al-fragment-based-drug-discovery-applied-to-hsp90-discovery-of-two-lead-series-with-high-ligand-efficiency-journal-of-medicinal-chemistry-53-no-16-2010-5942-5955-doi-10-1/ 2016-11-29T12:21:35+00:00 monthly 0.2 https://astx.com/mchardy-et-al-discovery-of-4-amino-1-7h-pyrrolo23-dpyrimidin-4-ylpiperidine-4-carboxamides-as-selective-orally-active-inhibitors-of-protein-kinase-b-akt-journal-of-medicinal-chemistry-53/ 2016-11-29T12:21:12+00:00 monthly 0.2 https://astx.com/dawson-m-a-et-al-at9283-a-potent-inhibitor-of-the-aurora-kinases-and-jak2-has-therapeutic-potential-in-myeloproliferative-disorders-british-journal-of-haematology-150-no-1-2010-46-57-doi/ 2016-11-29T12:20:37+00:00 monthly 0.2 https://astx.com/christopher-w-murray-and-tom-l-blundell-structural-biology-in-fragment-based-drug-design-current-opinion-in-structural-biology-20-no-4-2010-497-507-doi-10-1016j-sbi-2010-04-003/ 2016-11-29T12:19:56+00:00 monthly 0.2 https://astx.com/cho-et-al-4-pyrazol-4-yl-pyrimidines-as-selective-inhibitors-of-cyclin-dependent-kinase-46-journal-of-medicinal-chemistry-53-no-22-2010-7938-7957-doi-10-1021jm100571n/ 2016-11-29T12:06:57+00:00 monthly 0.2 https://astx.com/encouraging-data-on-astexs-anti-cancer-drug-at9283-to-be-presented-at-ash/ 2016-11-24T16:15:28+00:00 monthly 0.2 https://astx.com/supergen-announces-presentation-of-sgi-110-preclinical-data-at-american-society-of-hematology/ 2016-11-24T16:12:51+00:00 monthly 0.2 https://astx.com/supergen-announces-enrollment-of-first-patient-in-first-in-human-trial-of-sgi-110-in-mds-and-aml-patients/ 2016-11-24T15:09:45+00:00 monthly 0.2 https://astx.com/astex-announces-milestone-in-oncology-collaboration/ 2016-11-24T15:08:13+00:00 monthly 0.2 https://astx.com/astex-receives-milestone-from-wellcome-trust-for-pioneering-hcv-research/ 2016-11-24T15:05:46+00:00 monthly 0.2 https://astx.com/supergen-reports-2010-fourth-quarter-and-year-end-financial-results/ 2016-11-24T15:03:43+00:00 monthly 0.2 https://astx.com/astex-to-present-data-from-its-fgfr-inhibitor-programme-at-the-american-association-for-cancer-research-aacr-102nd-annual-meeting-2011/ 2016-11-24T15:02:12+00:00 monthly 0.2 https://astx.com/supergen-pim-kinase-presentations-at-aacr/ 2016-11-24T14:58:04+00:00 monthly 0.2 https://astx.com/supergen-to-webcast-5th-annual-investor-analyst-day-on-april-12-2011/ 2016-11-24T15:00:15+00:00 monthly 0.2 https://astx.com/supergen-and-astex-therapeutics-enter-definitive-merger-agreement/ 2016-11-24T14:55:13+00:00 monthly 0.2 https://astx.com/astex-announces-commencement-of-phase-i-study-for-azd5363-in-anti-cancer-collaboration-with-astrazeneca/ 2016-11-24T14:47:11+00:00 monthly 0.2 https://astx.com/3494-2/ 2016-12-01T16:45:11+00:00 monthly 0.2 https://astx.com/astex-achieves-milestones-in-gsk-collaboration/ 2016-11-24T14:49:31+00:00 monthly 0.2 https://astx.com/astex-therapeutics-and-cambridge-crystallographic-data-centre-extend-10-year-research-collaboration/ 2016-11-24T14:42:46+00:00 monthly 0.2 https://astx.com/eisai-and-janssen-announce-the-presentation-of-dacogen-decitabine-data-at-asco-from-a-phase-iii-study-in-patients-with-acute-myeloid-leukemia/ 2016-11-24T14:51:27+00:00 monthly 0.2 https://astx.com/supergen-stockholders-approve-stock-issuance-in-connection-with-the-proposed-acquisition-of-astex-therapeutics-limited/ 2016-11-24T14:52:03+00:00 monthly 0.2 https://astx.com/supergen-president-ceo-elected-to-bio-board-of-directors/ 2016-11-24T14:52:39+00:00 monthly 0.2 https://astx.com/fda-accepts-dacogen-decitabine-snda-submission-in-acute-myeloid-leukemia/ 2016-11-24T14:53:11+00:00 monthly 0.2 https://astx.com/supergen-reports-2011-second-quarter-financial-results/ 2016-11-24T14:53:59+00:00 monthly 0.2 https://astx.com/supergen-inc-changes-name-to-astex-pharmaceuticals-inc-announces-new-stock-ticker-symbol-and-new-website/ 2016-11-24T14:32:00+00:00 monthly 0.2 https://astx.com/evidence-of-at13387-activity-in-gastrointestinal-stromal-tumor-models-presented-at-ecco/ 2016-11-24T14:30:32+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-present-a-novel-targeted-approach-to-the-treatment-of-hcv-at-the-aasld-meeting/ 2016-11-24T14:15:53+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2011-third-quarter-financial-results/ 2016-11-24T14:24:53+00:00 monthly 0.2 https://astx.com/2011-eortc-phase-1-study-of-at7519m-short-infusion-twice-weekly/ 2016-11-25T14:05:41+00:00 monthly 0.2 https://astx.com/2011-eortc-at13387-anti-tumor-activity-in-imatinib-sensitive-and-resistant-gist-models/ 2016-11-25T15:25:05+00:00 monthly 0.2 https://astx.com/2011-tat_discovery-and-development-of-next-generation-epigenetic-dnmt-inhibitor-sgi-110/ 2016-12-01T12:36:45+00:00 monthly 0.2 https://astx.com/2011-tat_discovery-and-development-of-next-generation-epigenetic-dnmt-inhibitor-sgi-110-2/ 2016-11-25T16:41:48+00:00 monthly 0.2 https://astx.com/yap-et-al-preclinical-pharmacology-antitumor-activity-and-development-of-pharmacodynamic-markers-for-the-novel-potent-akt-inhibitor-cct128930-molecular-cancer-therapeutics-10-no-2-2011-360/ 2016-11-29T11:14:43+00:00 monthly 0.2 https://astx.com/williams-glyn-the-pyramid-approach-to-fragment-based-biophysical-screening-in-label-free-technologies-for-drug-discovery-edited-by-matthew-cooper-and-lorenz-m-mayr-241-253-chichester-uk-j/ 2016-11-29T11:14:20+00:00 monthly 0.2 https://astx.com/verdonk-et-al-docking-performance-of-fragments-and-drug-like-compounds-journal-of-medicinal-chemistry-54-no-15-2011-5422-5431-doi-10-1021jm200558u/ 2016-11-29T11:13:58+00:00 monthly 0.2 https://astx.com/squires-et-al-potent-selective-inhibitors-of-fibroblast-growth-factor-receptor-define-fibroblast-growth-factor-dependence-in-pre-clinical-cancer-models-molecular-cancer-therapeutics-10-no-22/ 2016-11-29T11:13:35+00:00 monthly 0.2 https://astx.com/santo-et-al-antimyeloma-activity-of-a-multitargeted-kinase-inhibitor-at9283-via-potent-aurora-kinase-and-stat3-inhibition-either-alone-or-in-combination-with-lenalidomide-clinical-cancer-resea/ 2016-11-29T11:13:11+00:00 monthly 0.2 https://astx.com/qi-et-al-at9283-a-novel-aurora-kinase-inhibitor-suppresses-tumor-growth-in-aggressive-b-cell-lymphomas-international-journal-of-cancer-2011-doi-10-1002ijc-26324/ 2016-11-29T11:12:48+00:00 monthly 0.2 https://astx.com/podesta-et-al-adaptation-of-the-plasma-inhibitory-activity-assay-to-detect-aurora-abl-and-flt3-kinase-inhibition-by-at9283-in-pediatric-leukemia-leukemia-research-35-no-9-2011-1273-1275-doi/ 2016-11-29T11:12:22+00:00 monthly 0.2 https://astx.com/paul-n-mortenson-and-christopher-w-murray-assessing-the-lipophilicity-of-fragments-and-early-hits-journal-of-computer-aided-molecular-design-25-no-7-2011-663-667-doi-10-1007s10822-011-94/ 2016-11-29T11:11:58+00:00 monthly 0.2 https://astx.com/mahadevan-et-al-a-phase-i-pharmacokinetic-and-pharmacodynamic-study-of-at7519-a-cyclin-dependent-kinase-inhibitor-in-patients-with-refractory-solid-tumors-annals-of-oncology-22-no-9-2011-213/ 2016-11-29T11:11:34+00:00 monthly 0.2 https://astx.com/heightman-tom-d-therapeutic-prospects-for-epigenetic-modulation-expert-opinion-on-therapeutic-targets-15-no-6-2011-729-740-doi-10-151714728222-2011-561786/ 2016-11-29T11:11:02+00:00 monthly 0.2 https://astx.com/brito-et-al-comparative-pre-clinical-evaluation-of-receptor-tyrosine-kinase-inhibitors-for-the-treatment-of-multiple-myeloma-leukemia-research-35-no-9-2011-1233-1240-doi-10-1016j-leukres-2/ 2016-11-29T11:10:34+00:00 monthly 0.2 https://astx.com/arkenau-et-al-a-phase-i-dose-escalation-study-of-at9283-a-small-molecule-inhibitor-of-aurora-kinases-in-patients-with-advanced-solid-malignancies-annals-of-oncology-2011-doi-10-1093annoncm/ 2016-11-29T11:10:09+00:00 monthly 0.2 https://astx.com/alessandri-et-al-induction-of-eosinophil-apoptosis-by-the-cyclin-dependent-kinase-inhibitor-at7519-promotes-the-resolution-of-eosinophil-dominant-allergic-inflammation-plos-one-6-no-9-2011-e2/ 2016-11-29T11:09:39+00:00 monthly 0.2 https://astx.com/astex-announces-fda-odac-meeting-of-snda-application-for-dacogen-in-treatment-of-elderly-aml/ 2016-11-24T14:12:28+00:00 monthly 0.2 https://astx.com/astex-announces-early-transfer-of-epigenetics-project-to-gsk/ 2016-12-01T16:42:52+00:00 monthly 0.2 https://astx.com/fdas-oncologic-drugs-advisory-committee-odac-votes-to-not-support-benefitrisk-profile-of-dacogen-decitabine-in-acute-myeloid-leukemia/ 2016-12-01T16:42:48+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-host-annual-analyst-and-investor-day-on-march-27-2012/ 2016-12-01T16:42:45+00:00 monthly 0.2 https://astx.com/2012-thoracic-symposium-hsp90-inhibitor-at13387-effective-in-mutant-egfr-and-alk-positive-nsclc/ 2016-11-25T15:28:18+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2011-fourth-quarter-and-year-end-financial-results-on-march-5-2012/ 2016-12-01T16:42:42+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2011-fourth-quarter-and-year-end-financial-results/ 2016-12-01T16:42:38+00:00 monthly 0.2 https://astx.com/eisai-inc-receives-complete-response-letter-from-the-u-s-food-and-drug-administration-for-dacogen-decitabine-for-injection-snda-in-acute-myeloid-leukemia/ 2016-12-01T16:42:35+00:00 monthly 0.2 https://astx.com/2012-tat-anti-angiogenic-activity-of-fragment-derived-inhibitors-of-metap2/ 2016-11-25T13:53:56+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-march-27th-analyst-and-investor-day-agenda/ 2016-12-01T16:42:32+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-present-at-aacr-annual-meeting/ 2016-12-01T16:42:28+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-subcutaneous-sgi-110-interim-phase-12-mds-and-aml-data-presentation-at-aacr/ 2016-12-01T16:42:24+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-present-at26893-a-novel-targeted-approach-to-the-treatment-of-hcv-at-easl/ 2016-12-01T16:42:21+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2012-first-quarter-financial-results-on-april-30-2012/ 2016-12-01T16:42:18+00:00 monthly 0.2 https://astx.com/2012-aacr-scale-up-development-of-a-process-for-a-low-volume-subcutaneous-formulation-of-sgi-110/ 2016-12-01T12:38:27+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2012-first-quarter-financial-results/ 2016-12-01T16:42:13+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-present-at-asco-annual-meeting/ 2016-12-01T16:42:06+00:00 monthly 0.2 https://astx.com/2012-aacr-at13387-hsp90-inhibitor-effective-in-vemurafenib-sensitive-and-resistant-melanoma-model/ 2016-11-25T15:23:55+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-earns-5-4-million-milestone-on-phase-i-trial-initiation-of-a-fgfr-kinase-inhibitor/ 2016-12-01T16:42:01+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-initiation-of-the-phase-2-expansion-of-the-sgi-110/ 2016-12-01T16:41:58+00:00 monthly 0.2 https://astx.com/2012-tat-discovery-of-dual-antagonist-of-both-xiap-and-ciap-using-fragment-based-drug-discovery/ 2016-11-25T14:36:04+00:00 monthly 0.2 https://astx.com/astex-board-member-wins-2012-european-mediscience-award/ 2016-12-01T16:41:52+00:00 monthly 0.2 https://astx.com/dacogenr-receives-a-positive-regulatory-recommendation-in-the-european-union-for-treatment-of-acute-myeloid-leukemia/ 2016-12-01T16:41:39+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2012-second-quarter-financial-results-on-july-30/ 2016-11-24T13:00:50+00:00 monthly 0.2 https://astx.com/2012-asco-phase-i-study-assessing-qdx2-schedule-of-at13387-in-advanced-solid-tumors/ 2016-11-25T15:23:15+00:00 monthly 0.2 https://astx.com/2012-aacr-sgi-110-a-novel-sq-second-generation-dna-hypomethylating-agent/ 2016-12-01T12:38:10+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2012-second-quarter-financial-results/ 2016-11-24T13:01:05+00:00 monthly 0.2 https://astx.com/astex-president-awarded-prous-institute-overton-and-meyer-award-for-new-technologies-in-drug-discovery/ 2016-11-24T13:01:20+00:00 monthly 0.2 https://astx.com/2012-aacr-discovery-of-potent-dual-inhibitors-of-both-xiap-and-ciap-using-fragment-based/ 2016-11-25T14:35:36+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-participate-on-epigenetics-panel-at-rodman-renshaw-conference/ 2016-11-24T13:01:36+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-cancer-research-technology-and-the-institute-of-cancer-research-announce-epigenetic-drug-discovery-collaboration/ 2016-11-24T13:01:54+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-initiation-of-hsp90-inhibitor-at13387-clinical-trial-in-prostate-cancer-patients/ 2016-11-24T13:02:12+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-discontinues-amuvatinib-clinical-development-program/ 2016-11-24T13:02:29+00:00 monthly 0.2 https://astx.com/2012-ascofih-phase-i-study-results-of-hsp90-inhibitor-at13387-in-refractory-solid-tumors/ 2016-11-25T15:22:22+00:00 monthly 0.2 https://astx.com/2012-aacr-chemosensitizing-effects-of-dna-methylation-inhibitor-sgi-110-in-ovarian-cancer/ 2016-12-01T12:37:51+00:00 monthly 0.2 https://astx.com/dacogenr-approved-in-the-european-union-for-the-treatment-of-acute-myeloid-leukemia/ 2016-11-24T13:03:05+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-initiation-of-sgi-110-phase-2-trial-in-platinum-resistant-recurrent-ovarian-cancer-patients/ 2016-11-24T13:03:24+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-earns-5-million-for-first-commercial-sale-of-dacogenr-in-the-european-union/ 2016-11-24T13:03:42+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-the-appointment-of-president-harren-jhoti-phd-to-the-bioindustry-association-board-of-directors/ 2016-11-24T13:04:08+00:00 monthly 0.2 https://astx.com/astex-scientists-publish-the-discovery-of-novel-allosteric-modulators-for-the-key-therapeutic-targets-hcv-ns3-and-pkm2-in-nature-journals/ 2016-11-24T13:04:53+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2012-third-quarter-financial-results-on-october-30/ 2016-11-24T13:05:16+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-initiation-of-at13387-phase-2-study-in-non-small-cell-lung-cancer/ 2016-12-01T16:41:32+00:00 monthly 0.2 https://astx.com/aacr-pharmacodynamic-and-anti-tumor-activity-of-fragment-derived-inhibitors-of-metap2/ 2016-11-24T12:58:12+00:00 monthly 0.2 https://astx.com/2012-eortc-characterization-of-a-potent-xiap-ciap1-dual-antagonist-in-melanoma-and-leukemia/ 2016-11-25T14:35:08+00:00 monthly 0.2 https://astx.com/2012-eortc-sgi-110-enhances-sorafenib-activity-and-alters-methylation-signature-of-hcc-cell-lines/ 2016-12-01T12:37:33+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-cancer-research-technology-and-newcastle-university-sign-strategic-drug-discovery-alliance/ 2016-12-01T16:41:27+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2012-third-quarter-financial-results/ 2016-11-24T12:59:11+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-present-at-eortc-nci-aacr/ 2016-11-24T12:58:47+00:00 monthly 0.2 https://astx.com/2012-aacr-scale-up-development-of-a-process-for-a-low-volume-subcutaneous-formulation-of-sgi-110-2/ 2016-11-25T16:39:52+00:00 monthly 0.2 https://astx.com/2012-aacr-sgi-110-a-novel-sq-second-generation-dna-hypomethylating-agent-2/ 2016-11-25T16:39:26+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-oral-presentation-of-sgi-110-results-from-phase-12-mds-and-aml-study-at-ash/ 2016-11-24T12:58:20+00:00 monthly 0.2 https://astx.com/2012-aacr-chemosensitizing-effects-of-dna-methylation-inhibitor-sgi-110-in-ovarian-cancer-2/ 2016-11-25T16:38:58+00:00 monthly 0.2 https://astx.com/pyruvate-kinase-m2-linking-glycolysis-to-amino-acid-biosynthesis/ 2024-02-12T16:05:12+00:00 monthly 0.2 https://astx.com/2012-eortc-sgi-110-enhances-sorafenib-activity-and-alters-methylation-signature-of-hcc-cell-lines-2/ 2016-11-25T16:38:33+00:00 monthly 0.2 https://astx.com/2012-apoptosis-and-cancer-a-potent-xiap-and-ciap1-dual-antagonist-is-effective-in-melanoma-models/ 2016-11-25T14:34:40+00:00 monthly 0.2 https://astx.com/2012-eortc-activity-of-the-hsp90-inhibitor-at13387-in-alk-driven-tumor-models/ 2016-11-25T15:21:39+00:00 monthly 0.2 https://astx.com/2012-ash-results-from-dose-escalation-phase-of-randomized-phase-1-2-fih-study-of-sgi-110/ 2016-12-01T12:37:19+00:00 monthly 0.2 https://astx.com/2012-ash-results-from-dose-escalation-phase-of-randomized-phase-1-2-fih-study-of-sgi-110-2/ 2016-11-25T16:38:00+00:00 monthly 0.2 https://astx.com/experiences-of-fragment-based-drug-discovery/ 2016-11-29T10:57:58+00:00 monthly 0.2 https://astx.com/the-hsp90-inhibitor-at13387-is-effective-against-imatinib-sensitve-and-resistant-gastrointestinal-stromal-tumours/ 2016-11-29T10:57:34+00:00 monthly 0.2 https://astx.com/fragment-screening-using-x-ray-crystallography/ 2016-11-29T11:07:49+00:00 monthly 0.2 https://astx.com/discovery-of-an-allosteric-mechanism-for-the-regulation-of-hcv-ns3-protein-function/ 2016-11-29T11:07:43+00:00 monthly 0.2 https://astx.com/serine-is-a-natural-ligand-and-allosteric-activator-of-pyruvate-kinase-m2/ 2016-11-29T11:07:24+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-december-14th-analyst-and-investor-day-agenda/ 2016-11-24T12:57:40+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-results-from-dose-escalation-part-of-sgi-110-phase-12-mds-and-aml-study-in-an-oral-presentation-at-ash/ 2016-11-24T12:57:14+00:00 monthly 0.2 https://astx.com/nature-serine-is-a-natural-ligand-and-allosteric-activator-of-pyruvate-kinase-m2/ 2024-02-12T16:05:21+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-initiation-of-sgi-110-phase-2-trial-in-advanced-hepatocellular-carcinoma-hcc-patients/ 2016-11-24T12:55:51+00:00 monthly 0.2 https://astx.com/cancer-research-uk-and-cancer-research-technology-initiate-at13148-clinical-trial-to-treat-several-cancer-types/ 2016-11-24T12:52:31+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2012-fourth-quarter-and-year-end-financial-results-on-february-25th/ 2016-11-24T12:52:10+00:00 monthly 0.2 https://astx.com/2013-tat-immunomodulatory-activity-of-sgi-110-a-second-generation-hypomethylating-agent/ 2016-12-01T12:46:53+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2012-fourth-quarter-and-year-end-financial-results/ 2016-11-24T12:50:37+00:00 monthly 0.2 https://astx.com/2013-aacr-evaluation-oral-bioavailability-and-intermittent-dosing-schedule-for-pd-effects-by-sgi-110/ 2016-12-01T12:46:39+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-pipeline-data-presentations-at-aacr/ 2016-11-24T12:50:17+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-provides-sgi-110-update/ 2016-11-24T12:49:58+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2013-first-quarter-financial-results-on-april-29th/ 2016-12-01T16:36:50+00:00 monthly 0.2 https://astx.com/2013-aacr-in-vivo-immunomodulatory-activity-of-sgi-110-a-second-generation-hypomethylating-agent/ 2016-12-01T12:46:22+00:00 monthly 0.2 https://astx.com/2013-aacr-at-iap-a-dual-ciap1-and-xiap-antagonist-with-oral-antitumor-activity-in-melanoma-models/ 2016-11-25T14:34:01+00:00 monthly 0.2 https://astx.com/2013-aacr-novel-small-molecule-dna-methylation-inhibitor-sgi-110-as-ovarian-cancer-chemosensitizer/ 2016-12-01T12:46:05+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2013-first-quarter-financial-results/ 2016-12-01T16:36:54+00:00 monthly 0.2 https://astx.com/2013-eha-outcomes-of-intermediate-or-high-risk-mds-patients-post-azacitidine-and-or-decitabine/ 2016-12-01T12:45:50+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-presentation-of-updated-results-of-sgi-110-01-study-in-patients-with-intermediate-or-high-risk-relapsed-or-refractory-myelodysplastic-syndromes-at-the-european-hematolo/ 2016-12-01T16:36:58+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-oral-presentation-of-sgi-110-data-at-the-upcoming-european-cancer-congress-ecco-esmo-estro/ 2016-12-01T16:37:03+00:00 monthly 0.2 https://astx.com/2013-eortc-epigenetic-priming-with-sgi-110-improved-antitumor-activity-of-ctla-4-blockade/ 2016-12-01T12:45:12+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-ind-candidate-astx727-a-potential-best-in-class-oral-hypomethylator/ 2016-12-01T16:37:09+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-first-data-showing-early-combination-treatment-of-resistance-in-preclinical-models/ 2016-11-24T12:49:35+00:00 monthly 0.2 https://astx.com/2013-gi-conference-at13387-a-novel-non-ansamycin-inhibitor-of-hsp-90-is-active-against-gist/ 2016-11-25T15:18:25+00:00 monthly 0.2 https://astx.com/2013-aacr-sgi-110-induces-cancer-germline-cg-antigen-expression-in-acute-myeloid-leukemia-cells/ 2016-12-01T12:44:38+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-to-announce-2013-second-quarter-financial-results-on-august-1st/ 2016-11-24T12:49:01+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-reports-2013-second-quarter-financial-results/ 2016-11-24T12:48:04+00:00 monthly 0.2 https://astx.com/2013-eortc-potent-dual-ciap1xiap-antagonists-induce-apoptosis-in-melanoma-stem-cell-population/ 2016-11-25T14:28:00+00:00 monthly 0.2 https://astx.com/2013-cell-symposia-cancer-epigenomics-anti-tumour-activity-of-sgi-110-a-novel-hypomethylating/ 2016-12-01T12:44:22+00:00 monthly 0.2 https://astx.com/mrcf-invests-au1m-in-antibiotics-start-up-astex/ 2016-11-24T12:47:49+00:00 monthly 0.2 https://astx.com/otsuka-pharmaceutical-to-acquire-astex-pharmaceuticals-for-8-50-per-share-in-cash/ 2016-12-02T14:29:11+00:00 monthly 0.2 https://astx.com/2013-iaslc-wclc-at13387-displays-single-agent-activity-in-erlotinib-sensitive-resistant-nsclc/ 2016-11-25T15:17:26+00:00 monthly 0.2 https://astx.com/2013-ash-dna-demethylation-activity-over-time-and-safety-regimens-of-sgi-110-in-rr-mds-and-aml-pts/ 2016-12-01T12:44:06+00:00 monthly 0.2 https://astx.com/astex-and-domainex-announce-collaboration-to-develop-new-drugs-to-treat-antibiotic-resistant-bacterial-infections/ 2016-11-24T12:47:29+00:00 monthly 0.2 https://astx.com/astex-secures-additional-au1million-from-mrcf-to-advance-its-antibiotic-pipeline-highly-experienced-team-secured/ 2016-11-24T12:47:12+00:00 monthly 0.2 https://astx.com/astex-raises-6million-to-progress-its-novel-antibiotics-and-establishes-uk-operations/ 2016-11-24T12:46:58+00:00 monthly 0.2 https://astx.com/2013-ash-determinants-of-demethylation-and-clinical-response-in-aml-patients-treated-with-sgi-110/ 2016-12-01T12:43:50+00:00 monthly 0.2 https://astx.com/2013-tat-immunomodulatory-activity-of-sgi-110-a-second-generation-hypomethylating-agent-2/ 2016-11-25T16:35:20+00:00 monthly 0.2 https://astx.com/2013-aacr-evaluation-oral-bioavailability-and-intermittent-dosing-schedule-for-pd-effects-by-sgi-11/ 2016-11-25T16:34:50+00:00 monthly 0.2 https://astx.com/2013-aacr-in-vivo-immunomodulatory-activity-of-sgi-110-a-second-generation-hypomethylating-agent-2/ 2016-11-25T16:34:26+00:00 monthly 0.2 https://astx.com/2013-aacr-novel-small-molecule-dna-methylation-inhibitor-sgi-110-as-ovarian-cancer-chemosensitizer-2/ 2016-11-25T16:33:52+00:00 monthly 0.2 https://astx.com/2013-eha-outcomes-of-intermediate-or-high-risk-mds-patients-post-azacitidine-and-or-decitabine-2/ 2016-11-25T16:33:26+00:00 monthly 0.2 https://astx.com/2013-eortc-epigenetic-priming-with-sgi-110-improved-antitumor-activity-of-ctla-4-blockade-2/ 2016-11-25T16:32:45+00:00 monthly 0.2 https://astx.com/2013-aacr-sgi-110-induces-cancer-germline-cg-antigen-expression-in-acute-myeloid-leukemia-cells-2/ 2016-11-25T16:32:15+00:00 monthly 0.2 https://astx.com/2013-ecco-study-of-correlation-baseline-biomarkers-and-dna-demethylation-to-clin-response-of-sgi-11/ 2016-11-25T16:31:50+00:00 monthly 0.2 https://astx.com/2013-cell-symposia-cancer-epigenomics-anti-tumour-activity-of-sgi-110-a-novel-hypomethylating-2/ 2016-11-25T16:31:14+00:00 monthly 0.2 https://astx.com/2013-ash-dna-demethylation-activity-over-time-and-safety-regimens-of-sgi-110-in-rr-mds-and-aml-pts-2/ 2016-11-25T16:30:46+00:00 monthly 0.2 https://astx.com/2013-ash-phase-iii-open-label-study-of-at7519-alone-and-in-combo-with-bortezomib-in-pts-with-mm-2/ 2016-11-25T13:59:42+00:00 monthly 0.2 https://astx.com/2013-rscsci-fragment-based-drug-discovery-of-a-potent-dual-antagonist-of-xiap-and-ciap1/ 2016-11-25T14:27:24+00:00 monthly 0.2 https://astx.com/2013-ash-preclin-data-in-cynomologus-monkeys-of-astx727-an-oral-hma-composed-of-decitabine-e7727/ 2016-11-25T14:42:46+00:00 monthly 0.2 https://astx.com/2013-worldmelanoma-combining-at13387-with-vemurafenib-delay-emergence-of-resistance-in-preclin-mode/ 2016-11-25T15:16:47+00:00 monthly 0.2 https://astx.com/2013-ash-first-clinical-results-of-a-randomized-phase-2-study-of-sgi-110-in-adult-patients-with-aml/ 2016-12-01T12:43:36+00:00 monthly 0.2 https://astx.com/2013-ash-determinants-of-demethylation-and-clinical-response-in-aml-patients-treated-with-sgi-110-2/ 2016-11-25T16:30:14+00:00 monthly 0.2 https://astx.com/2013-ash-first-clinical-results-of-a-randomized-phase-2-study-of-sgi-110-in-adult-patients-with-aml-2/ 2016-11-25T16:35:49+00:00 monthly 0.2 https://astx.com/saha-abrogates-flip-mediated-inhibition-of-smac-mimetic-induced-apoptosis-in-mesothelioma/ 2016-11-29T10:59:06+00:00 monthly 0.2 https://astx.com/the-rule-of-three-for-fragment-based-drug-discovery-where-are-we-now/ 2016-11-29T10:58:56+00:00 monthly 0.2 https://astx.com/fragment-based-discovery-of-6-azaindazoles-as-inhibitors-of-bacterial-dna-ligase/ 2016-11-29T10:58:46+00:00 monthly 0.2 https://astx.com/2014-aacr-sgi-110-dna-hma-sgi-110-reverses-platinum-resistance-of-ovarian-cancer-models/ 2016-12-01T12:49:38+00:00 monthly 0.2 https://astx.com/2014-clinical-epigenetics-international-meeting-identification-of-novel-biomarker-candidates/ 2016-12-01T12:49:58+00:00 monthly 0.2 https://astx.com/nature-biopharma-dealmakers-humabody-fragments-small-and-perfectly-formed/ 2016-12-01T16:34:15+00:00 monthly 0.2 https://astx.com/2014-cptt-novel-small-molecule-antagonists-of-xiap-and-ciap-generated-by-fragment-based-drug-discovery/ 2016-11-30T14:36:38+00:00 monthly 0.2 https://astx.com/2014-aacr-clinical-epigenetic-resensitization-of-platinum-resistant-recurrent-ovarian-cancer/ 2016-12-01T12:50:13+00:00 monthly 0.2 https://astx.com/2014-tat-hsp90-inhibition-by-at13387-can-overcome-delay-appearance-of-resistance-to-tki-in-lung/ 2016-11-25T15:15:52+00:00 monthly 0.2 https://astx.com/2014-aacr-sgi-110-sq-provides-superior-disposition-profile-for-active-metabolite-decitabine/ 2016-12-01T12:50:31+00:00 monthly 0.2 https://astx.com/astex-expands-board-of-directors-and-scientific-advisory-board/ 2016-12-01T16:34:00+00:00 monthly 0.2 https://astx.com/2014-asco-first-results-of-a-phase-2-study-using-a-10-day-sc-regimen-of-the-hma-sgi-110-for-rr-aml/ 2016-12-01T12:50:49+00:00 monthly 0.2 https://astx.com/2014-bacr-characterisation-of-the-activity-of-potent-xiapciap1-dual-antagonists-in-melanoma-models/ 2016-11-30T14:38:04+00:00 monthly 0.2 https://astx.com/2014-eha-results-of-a-randomized-multicenter-phase-2-study-of-a-5-day-regimen-of-sgi-110/ 2016-12-01T12:49:21+00:00 monthly 0.2 https://astx.com/2014-aacr-at13387-combined-with-erlotinib-improves-response-in-egfr-driven-xenograft-models-of-nscl/ 2016-11-30T16:26:02+00:00 monthly 0.2 https://astx.com/2014-esmo-comparison-of-efficacy-safety-5-day-10-day-schedules-of-sgi-110-treatment-of-rr-aml/ 2016-12-01T12:48:33+00:00 monthly 0.2 https://astx.com/2014-eortc-epigenetic-immunomodulation-by-sgi-110-combined-with-immune-check-point-blockade/ 2016-12-01T12:48:13+00:00 monthly 0.2 https://astx.com/2014-esmo-phase-12-of-at13387-hsp90-inhibitor-in-combo-with-abiraterone-acetate-and-prednisone/ 2016-11-30T16:38:51+00:00 monthly 0.2 https://astx.com/2014ash-identification-of-methylation-biomarkers-to-predict-clinical-response-to-sgi-110-in-aml-pts/ 2016-12-01T12:47:44+00:00 monthly 0.2 https://astx.com/2014-aacr-sgi-110-dna-hma-sgi-110-reverses-platinum-resistance-of-ovarian-cancer-models-2/ 2016-11-30T14:52:36+00:00 monthly 0.2 https://astx.com/2014-clinical-epigenetics-international-meeting-identification-of-novel-biomarker-candidates-2/ 2016-11-30T14:50:04+00:00 monthly 0.2 https://astx.com/2014-aacr-clinical-epigenetic-resensitization-of-platinum-resistant-recurrent-ovarian-cancer-2/ 2016-11-30T14:49:11+00:00 monthly 0.2 https://astx.com/2014-aacr-sgi-110-sq-provides-superior-disposition-profile-for-active-metabolite-decitabine-2/ 2016-11-30T14:46:49+00:00 monthly 0.2 https://astx.com/2014-asco-first-results-of-a-phase-2-study-using-a-10-day-sc-regimen-of-the-hma-sgi-110-for-rr-aml-2/ 2016-11-30T14:44:51+00:00 monthly 0.2 https://astx.com/2014-eha-results-of-a-randomized-multicenter-phase-2-study-of-a-5-day-regimen-of-sgi-110-2/ 2016-11-25T16:25:20+00:00 monthly 0.2 https://astx.com/2014-esmo-comparison-of-efficacy-safety-5-day-10-day-schedules-of-sgi-110-treatment-of-rr-aml-2/ 2016-11-25T16:24:51+00:00 monthly 0.2 https://astx.com/2014-eortc-epigenetic-immunomodulation-by-sgi-110-combined-with-immune-check-point-blockade-2/ 2016-11-30T14:41:51+00:00 monthly 0.2 https://astx.com/johnson-et-al-fragment-based-discovery-of-type-i-inhibitors-of-maternal-embryonic-leucine-zipper-kinase-acs-medicinal-chemistry-letters-doi10-1021ml5001245/ 2016-12-01T16:17:30+00:00 monthly 0.2 https://astx.com/2014ash-identification-of-methylation-biomarkers-to-predict-clinical-response-to-sgi-110-in-aml-pts-2/ 2016-11-30T14:40:25+00:00 monthly 0.2 https://astx.com/2014-eortc-induction-of-apoptosis-with-a-novel-dual-ciap1xiap-antagonist-in-models-of-melanoma/ 2016-11-30T14:31:23+00:00 monthly 0.2 https://astx.com/2014-esmo-study-of-hsp90-inhibitor-at13387-alone-and-combo-w-crizotinib-in-the-treatment-of-nsclc/ 2016-11-30T15:57:36+00:00 monthly 0.2 https://astx.com/2014-ash-first-clinical-results-of-p2-study-of-sgi-110-in-intermediate-or-high-risk-mds-or-cmml/ 2016-12-01T13:01:03+00:00 monthly 0.2 https://astx.com/2014-ash-first-clinical-results-of-p2-study-of-sgi-110-in-intermediate-or-high-risk-mds-or-cmml-2/ 2016-11-25T16:23:13+00:00 monthly 0.2 https://astx.com/2015-ascpt-systems-pharmacology-modeling-of-decitabine-and-sgi-110/ 2016-12-01T12:53:50+00:00 monthly 0.2 https://astx.com/2015-keystone-conf-dna-methylome-alterations-in-platinum-resistant-ovarian-cancer-tumors/ 2016-12-01T12:54:36+00:00 monthly 0.2 https://astx.com/2015-aacr-determinants-of-hypomethylation-and-clinical-response-in-rr-aml-pts-treated-with-sgi-110/ 2016-12-01T12:54:51+00:00 monthly 0.2 https://astx.com/2015-aacr-novel-combination-therapy-of-sgi-110-and-bmn-673-for-brca-proficient-ovarian-cancer/ 2016-12-01T12:55:11+00:00 monthly 0.2 https://astx.com/2015-aacr-pd-and-pk-results-of-sgi-110-in-patients-with-hcc-after-progression-on-sorafenib/ 2016-12-01T12:55:30+00:00 monthly 0.2 https://astx.com/2015-aacr-first-results-of-a-10-day-regimen-of-sgi-110-in-previously-untreated-elderly-aml/ 2016-12-01T12:53:23+00:00 monthly 0.2 https://astx.com/astex-and-domainex-expand-collaboration-to-develop-new-drugs-that-tackle-antibiotic-resistant-bacterial-infections/ 2016-12-01T16:33:37+00:00 monthly 0.2 https://astx.com/2015-tat-combination-of-onalespib-at13387-with-crizotinib-to-treat-or-delay-resistance-in-nsclc/ 2016-11-25T14:47:01+00:00 monthly 0.2 https://astx.com/2015-asco-epigenome-and-genome-alterations-in-platinum-resistant-ovarian-cancer/ 2016-12-01T12:51:49+00:00 monthly 0.2 https://astx.com/astex-appoints-dr-neil-miller-as-chief-scientific-officer/ 2016-12-01T16:33:21+00:00 monthly 0.2 https://astx.com/2015-eha-late-response-os-long-term-follow-up-of-randomized-p2-study-of-sgi-110-in-elderly-aml/ 2016-12-01T12:32:11+00:00 monthly 0.2 https://astx.com/2015-ascpt-systems-pharmacology-modeling-of-decitabine-and-sgi-110-2/ 2016-11-30T12:52:59+00:00 monthly 0.2 https://astx.com/2015-keystone-conf-dna-methylome-alterations-in-platinum-resistant-ovarian-cancer-tumors-2/ 2016-11-30T12:48:17+00:00 monthly 0.2 https://astx.com/2015-aacr-determinants-of-hypomethylation-and-clinical-response-in-rr-aml-pts-treated-with-sgi-110-2/ 2016-11-30T12:41:25+00:00 monthly 0.2 https://astx.com/2015-aacr-novel-combination-therapy-of-sgi-110-and-bmn-673-for-brca-proficient-ovarian-cancer-2/ 2016-11-30T12:24:26+00:00 monthly 0.2 https://astx.com/2015-aacr-pd-and-pk-results-of-sgi-110-in-patients-with-hcc-after-progression-on-sorafenib-2/ 2016-11-30T12:21:10+00:00 monthly 0.2 https://astx.com/2015-aacr-first-results-of-a-10-day-regimen-of-sgi-110-in-previously-untreated-elderly-aml-2/ 2016-11-30T12:18:14+00:00 monthly 0.2 https://astx.com/2015-asco-epigenome-and-genome-alterations-in-platinum-resistant-ovarian-cancer-2/ 2016-11-30T12:16:35+00:00 monthly 0.2 https://astx.com/2015_esh-aml-baseline-biomarkers-and-dna-demethylation-correlate-w-clinical-responses-in-sgi-110-2/ 2016-11-30T12:11:20+00:00 monthly 0.2 https://astx.com/2015-eha-late-response-os-long-term-follow-up-of-randomized-p2-study-of-sgi-110-in-elderly-aml-2/ 2016-11-30T12:08:31+00:00 monthly 0.2 https://astx.com/2015-ash-correlations-between-biomarkers-and-clinical-responses-in-phase-12-study-of-guadecitabine/ 2016-11-30T12:06:33+00:00 monthly 0.2 https://astx.com/2015-ash-results-of-fih-p1-pk-guided-dose-escalation-study-of-astx727-in-subjects-with-mds/ 2016-11-30T11:31:58+00:00 monthly 0.2 https://astx.com/2015-aacr-onalespib-delays-the-emergence-of-resistance-to-erlotinig-in-egfr-driven-xenograft-model/ 2016-11-30T13:17:00+00:00 monthly 0.2 https://astx.com/2015_esh-aml-baseline-biomarkers-and-dna-demethylation-correlate-w-clinical-responses-in-sgi-110/ 2016-12-01T12:12:43+00:00 monthly 0.2 https://astx.com/2015-ashcomparison-of-efficacy-safety-results-in-103-tn-aml-pts-using-5-10-day-regimens-sgi-110/ 2016-11-25T16:14:52+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-enters-clinical-trial-collaboration-to-explore-the-potential-of-combining-guadecitabine-sgi-110-with-atezolizumab-in-the-treatment-of-acute-myeloid-leukemia/ 2017-07-07T16:26:25+00:00 monthly 0.2 https://astx.com/tat-anti-angiogenic-activity-of-fragment-derived-inhibitors-of-metap2/ 2024-02-12T16:05:32+00:00 monthly 0.2 https://astx.com/fragment-based-drug-discovery-an-organic-synthesis-perspective/ 2024-02-12T16:05:42+00:00 monthly 0.2 https://astx.com/management-update/ 2016-11-23T15:38:43+00:00 monthly 0.2 https://astx.com/characterisation-of-fragments-binding-to-the-translation-initiation-factor-eif4e/ 2024-02-12T16:05:50+00:00 monthly 0.2 https://astx.com/key-oncology-data-on-humabody-drug-conjugates/ 2016-12-01T16:20:58+00:00 monthly 0.2 https://astx.com/59th-ash-annual-meeting-exposition/ 2018-01-16T18:32:08+00:00 monthly 0.2 https://astx.com/psdi-2017/ 2018-01-16T18:32:22+00:00 monthly 0.2 https://astx.com/aacr-nci-eortc/ 2018-01-16T18:32:31+00:00 monthly 0.2 https://astx.com/eha-congress-of-the-european-hematology-association/ 2017-05-09T16:20:22+00:00 monthly 0.2 https://astx.com/asco-annual-meeting/ 2018-01-16T18:31:44+00:00 monthly 0.2 https://astx.com/2016-tat-guadecitabine-sgi-110-a-novel-partner-in-immunotherapy/ 2016-11-30T10:30:31+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting/ 2018-01-16T18:31:17+00:00 monthly 0.2 https://astx.com/2016-esh-mds-results-of-a-p2-study-of-sgi-110-in-pts-with-rr-intermediate-or-high-risk-mds-or-cmml/ 2016-11-30T10:24:16+00:00 monthly 0.2 https://astx.com/2016-aacr-immune-checkpoints-expression-in-aml-pts-enrolled-in-phase-1-2-study-with-guadecitabine/ 2016-11-30T10:16:33+00:00 monthly 0.2 https://astx.com/astex-joins-the-dementia-discovery-fund-as-a-strategic-investor/ 2016-12-01T16:32:42+00:00 monthly 0.2 https://astx.com/in-gel-activity-based-protein-profiling-of-a-clickable-covalent-erk12-inhibitor/ 2016-11-24T12:43:05+00:00 monthly 0.2 https://astx.com/murray-et-al-opportunity-knocks-organic-chemistry-for-fragment-based-drug-discovery-fbdd-angewandte-chemie-3-november-2015-doi-10-1002anie-201506783-2/ 2016-11-30T11:21:16+00:00 monthly 0.2 https://astx.com/palmer-et-al-design-and-synthesis-of-dihydroisoquinolones-for-fragment-based-drug-discovery-fbdd-org-biomol-chem-201614-1599-1610/ 2021-09-28T14:02:35+00:00 monthly 0.2 https://astx.com/davies-et-al-mono-acidic-inhibitors-of-the-keap1-kelch-nrf2-protein-protein-interaction-with-high-cell-potency-identified-by-fragment-based-discovery-j-med-chem-31-march-2016-doi-10-1021/ 2021-09-28T13:54:50+00:00 monthly 0.2 https://astx.com/murray-et-al-opportunity-knocks-organic-chemistry-for-fragment-based-drug-discovery-fbdd-angewandte-chemie-3-november-2015-doi-10-1002anie-201506783/ 2016-12-01T16:31:20+00:00 monthly 0.2 https://astx.com/woolford-et-al-exploitation-of-a-novel-binding-pocket-in-human-lipoprotein-associated-phospholipase-a2-lp-pla2-discovered-through-x-ray-fragment-screening-j-med-chem-27-may-2016-doi-10-102/ 2021-09-28T13:53:30+00:00 monthly 0.2 https://astx.com/amin-et-al-1h-15n-and-13c-backbone-assignments-of-gdp-bound-human-h-ras-mutant-g12v-springer-link-15-september-2015-doi-10-1007s12104-015-9649-4/ 2016-11-30T11:17:35+00:00 monthly 0.2 https://astx.com/keseru-et-al-design-principles-for-fragment-libraries-maximizing-the-value-of-learnings-from-pharma-fragment-based-drug-discovery-fbdd-programs-for-use-in-academia-j-med-chem-april-2016-do/ 2021-09-28T13:52:18+00:00 monthly 0.2 https://astx.com/amin-et-al-nmr-backbone-resonance-assignment-and-solution-secondary-structure-determination-of-human-nsd1-and-nsd2-biomol-nmr-assign-29-june-2016-doi10-1007s12104-016-9691-x/ 2021-09-28T13:50:52+00:00 monthly 0.2 https://astx.com/chessari-et-al-fragment-based-drug-discovery-targeting-inhibitor-of-apoptosis-proteins-discovery-of-a-non-alanine-lead-series-with-dual-activity-against-ciap1-and-xiap-journal-of-medical-chemi/ 2016-11-30T11:14:05+00:00 monthly 0.2 https://astx.com/verdonk-et-al-protein-ligand-informatics-force-field-pliff-toward-a-fully-knowledge-driven-force-field-for-biomolecular-interactions-j-med-chem-2016-59-14/ 2021-09-28T14:07:51+00:00 monthly 0.2 https://astx.com/day-et-al-the-synthesis-of-33-dimethyl-aza-and-diazaindolines-using-a-palladium-catalysed-intramolecular-reductive-cyclisation-thieme-2015-doi-10-1055s-0035-1560320/ 2016-11-30T11:12:53+00:00 monthly 0.2 https://astx.com/lebraud-et-al-in-gel-activity-based-protein-profiling-of-a-clickable-covalent-erk12-inhibitor-mol-biosyst-201612-2867-2874-doi-10-1039c6mb00367b/ 2021-09-28T13:47:11+00:00 monthly 0.2 https://astx.com/ludlow-et-al-detection-of-secondary-binding-sites-in-proteins-using-fragment-screening-pnas-11-december-2015-www-pnas-orgcgidoi10-1073pnas-1518946112/ 2016-11-30T11:09:26+00:00 monthly 0.2 https://astx.com/erlanson-et-al-twenty-years-on-the-impact-of-fragments-on-drug-discovery-nature-reviews-drug-discovery-2016-doi10-1038nrd-2016-109/ 2021-09-28T13:45:44+00:00 monthly 0.2 https://astx.com/murray-et-al-fragment-based-discovery-of-potent-and-selective-ddr12-inhibitors-acs-med-chem-lett-4-june-2015/ 2016-11-30T11:04:44+00:00 monthly 0.2 https://astx.com/issa-et-al-safety-and-tolerability-of-guadecitabine-sgi-110-in-patients-with-myelodysplastic-syndrome-and-acute-myeloid-leukaemia-a-multicentre-randomised-dose-escalation-phase-1-study-la/ 2016-11-30T11:02:45+00:00 monthly 0.2 https://astx.com/cleasby-et-al-structure-of-the-btb-domain-of-keap1-and-its-interaction-with-the-triterpenoid-antagonist-cddo-plos-one-4-june-2014-doi-10-1371journal-pone-0098896/ 2016-11-30T14:20:23+00:00 monthly 0.2 https://astx.com/hall-et-al-efficient-exploration-of-chemical-space-by-fragment-based-screening-science-direct-28-september-2014-doi-10-1016j-pbiomolbio-2014-09-007/ 2016-11-30T14:19:16+00:00 monthly 0.2 https://astx.com/saalau-bethell-et-al-crystal-structure-of-human-soluble-adenylate-cyclase-reveals-a-distinct-highly-flexible-allosteric-bicarbonate-binding-pocket-chemmedchem-24-february-2014-doi-10-1002c/ 2016-11-30T14:18:08+00:00 monthly 0.2 https://astx.com/shapiro-et-al-first-in-human-phase-i-dose-escalation-study-of-a-second-generation-non-ansamycin-hsp90-inhibitor-at13387-in-patients-with-advanced-solid-tumors-clinical-cancer-research-21-oct/ 2016-11-30T14:15:37+00:00 monthly 0.2 https://astx.com/saxty-et-al-identification-of-orally-bioavailable-small-molecule-inhibitors-of-hematopoietic-prostaglandin-d2-synthase-using-x-ray-fragment-based-drug-discovery-med-chem-commun-vol-5-2014/ 2016-11-30T14:14:13+00:00 monthly 0.2 https://astx.com/hopkins-et-al-the-role-of-ligand-efficiency-metrics-in-drug-discovery-nature-reviews-drug-discovery-vol-13-2014-105-121-doi-10-1038nrd4163/ 2016-11-30T14:13:01+00:00 monthly 0.2 https://astx.com/johnson-et-al-structure-based-design-of-type-ii-inhibitors-applied-to-maternal-embryonic-leucine-zipper-kinase-acs-medicinal-chemistry-letters-doi-10-1021ml5001273/ 2016-11-30T14:11:46+00:00 monthly 0.2 https://astx.com/chen-et-al-a-phase-1-study-of-cyclin-dependent-kinase-inhibitor-at7519-in-patients-with-advanced-cancer-ncic-clinical-trials-group-ind-177-br-j-cancer-2014-dec-9-111122262-7/ 2016-11-30T14:10:05+00:00 monthly 0.2 https://astx.com/smyth-et-al-inhibition-of-hsp90-by-at13387-delays-the-emergence-of-resistance-to-braf-inhibitors-and-overcomes-resistance-to-dual-braf-and-mek-inhibition-in-melanoma-models-mol-cancer-ther-2014/ 2016-11-30T14:08:46+00:00 monthly 0.2 https://astx.com/fang-et-al-the-novel-small-molecule-dna-methylation-inhibitor-sgi-110-as-an-ovarian-cancer-chemosensitizer-clin-cancer-res-2024-december-15-2014/ 2016-11-30T14:07:25+00:00 monthly 0.2 https://astx.com/2016-epigenetic-resensitization-in-recurrent-platinum-resistant-oc-using-sgi-110-phase-2-results-2/ 2024-02-12T16:28:16+00:00 monthly 0.2 https://astx.com/2016-eha-phase-1-dose-escalation-study-of-astx727-comparable-variability-in-pharmacokinetics/ 2024-02-12T16:20:30+00:00 monthly 0.2 https://astx.com/2016-aacr-dual-iap-antagonist-astx660-increases-anti-tumor-activity-of-paclitaxel-in-tnbc-models/ 2024-02-12T16:09:21+00:00 monthly 0.2 https://astx.com/2016addition-of-onalespib-to-crizotinib-prior-to-progression-in-pts-with-alk-pos-nsclc-p2-results/ 2016-11-30T09:27:48+00:00 monthly 0.2 https://astx.com/2016-eha-os-and-subgroup-results-from-randomized-phase-2-study-of-sgi-110-in-previously-treated-mds/ 2024-02-12T16:28:34+00:00 monthly 0.2 https://astx.com/astex-to-showcase-its-next-generation-hypomethylating-agents-being-developed-for-treatment/ 2016-12-02T09:48:20+00:00 monthly 0.2 https://astx.com/protein-degradation-by-in-cell-self-assembly-of-proteolysis-targeting-chimeras/ 2021-09-28T13:44:35+00:00 monthly 0.2 https://astx.com/2016-ash-long-term-survival-and-clinical-complete-responses-of-various-prognostic-subgroups-in-103-relapsedrefractory-acute-myeloid-leukemia-rr-aml-patients-treated-with-guadecitabine-sgi-110-i/ 2024-02-12T16:28:44+00:00 monthly 0.2 https://astx.com/2016-ash-genetic-determinants-of-response-to-guadecitabine-sgi-110-in-aml/ 2024-02-12T16:28:53+00:00 monthly 0.2 https://astx.com/2016-ash-successful-emulation-of-iv-decitabine-pharmacokinetics-with-an-oral-fixed-dose-combination-of-the-oral-cytidine-deaminase-inhibitor-cdai-e7727-with-oral-decitabine-in-subjects-with-myelod/ 2024-02-12T16:20:45+00:00 monthly 0.2 https://astx.com/cambridge-based-astex-pharmaceuticals-celebrates-as-cancer-drug-receives-us-marketing-approval/ 2017-03-14T09:57:55+00:00 monthly 0.2 https://astx.com/woolford-et-al-fragment-based-approach-to-the-development-of-an-orally-bioavailable-lactam-inhibitor-of-lipoprotein-associated-phospholipase-a2-lp-pla2-j-med-chem-2016-59-23-pp-10738/ 2021-09-28T13:43:15+00:00 monthly 0.2 https://astx.com/johnson-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2015-j-med-chem-2017-60-1-pp-89-99-doi-10-1021acs-jmedchem-6b01123/ 2021-09-28T13:39:17+00:00 monthly 0.2 https://astx.com/tisi-et-al-structure-of-the-epigenetic-oncogene-mmset-and-inhibition-by-n-alkyl-sinefungin-derivatives-acs-chem-biol-2016-11-11-pp-3093-3105-doi-10-1021acschembio-6b00308/ 2021-09-28T13:41:52+00:00 monthly 0.2 https://astx.com/2017-ascpt-development-of-a-semi-mechanistic-pkpd-model-of-an-oral-fixed-dose-combination-fdc-of-cytidine-deaminase-inhibitor-e7727-with-decitabine-astx727-in-subjects-with-myelodysplastic-syndr/ 2024-02-12T16:21:07+00:00 monthly 0.2 https://astx.com/2017-14th-intl-symposium-on-mds-randomized-phase-2-study-of-guadecitabine-in-patients-with-hma-naive-higher-risk-myelodysplastic-syndromes-mds-or-chronic-myelomonocytic-leukemia-cmml/ 2024-02-12T16:29:02+00:00 monthly 0.2 https://astx.com/2017-eha-dose-confirmation-study-of-oral-astx727-a-combination-of-oral-decitabine-with-a-cytidine-deaminase-inhibitor-cdai-e7727-in-subjects-with-myelodysplastic-syndromes-mds-preliminary-resu/ 2024-02-12T16:21:24+00:00 monthly 0.2 https://astx.com/2017-acop8-evaluation-of-potential-doses-and-regimens-of-an-oral-fixed-dose-combination-of-cytidine-deaminase-inhibitor-e7727-with-decitabine-astx727-to-minimize-decitabine-mediated-neutropenia-in/ 2024-02-12T16:21:38+00:00 monthly 0.2 https://astx.com/rathi-et-al-predicting-hot-and-warm-spots-for-fragment-binding-j-med-chem-2017-60-9-pp-4036-4046-doi-10-1021acs-jmedchem-7b00366/ 2021-09-28T13:37:26+00:00 monthly 0.2 https://astx.com/tamanini-et-al-discovery-of-a-potent-nonpeptidomimetic-small-molecule-antagonist-of-cellular-inhibitor-of-apoptosis-protein-1-ciap1-and-x-linked-inhibitor-of-apoptosis-protein-xiap-j-med/ 2021-09-28T13:35:42+00:00 monthly 0.2 https://astx.com/hall-et-al-the-fragment-network-a-chemistry-recommendation-engine-built-using-a-graph-database-j-med-chem-2017-6014-pp-6440-6450-doi-10-1021acs-jmedchem-7b00809/ 2021-09-28T13:33:32+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-celebrates-as-cancer-drug-receives-marketing-approval-in-europe/ 2017-08-24T16:02:59+00:00 monthly 0.2 https://astx.com/2017-accp-population-pharmacokinetics-analysis-for-guadecitabine-sgi-110-and-decitabine-after-subcutaneous-dosing-with-sgi-110-in-patients-with-relapsedrefractory-aml-and-mds/ 2024-02-12T16:29:12+00:00 monthly 0.2 https://astx.com/2017-esh-aml-line-1-and-p15-demethylation-may-predict-response-to-guadecitabine/ 2024-02-12T16:29:20+00:00 monthly 0.2 https://astx.com/2017-eortc-phase-1-study-of-the-iap-inhibitor-astx660-in-adults-with-advanced-cancers-and-lymphomas/ 2024-02-12T16:09:34+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-2018/ 2018-01-18T18:46:32+00:00 monthly 0.2 https://astx.com/otsuka-signs-statement-of-support-for-womens-empowerment-principles/ 2018-01-19T06:36:10+00:00 monthly 0.2 https://astx.com/2017-ash-a-phase-2-dose-confirmation-study-of-oral-astx727-a-combination-of-oral-decitabine-with-a-cytidine-deaminase-inhibitor-cdai-cedazuridine-e7727-in-subjects-with-myelodysplastic-syndrome/ 2024-02-12T16:22:05+00:00 monthly 0.2 https://astx.com/2017-ash-predictors-of-response-and-survival-in-206-aml-patients-treated-with-guadecitabine-in-a-phase-2-study/ 2024-02-12T16:29:34+00:00 monthly 0.2 https://astx.com/harren-jhoti-receives-lifetime-achievement-award-from-the-uk-bioindustry-association/ 2018-01-26T09:51:46+00:00 monthly 0.2 https://astx.com/astex-continues-to-deliver-in-oncology-as-erdafitinib-a-potential-new-treatment-for-metastatic-urothelial-cancer-receives-us-fda-breakthrough-therapy-designation/ 2018-03-15T14:01:46+00:00 monthly 0.2 https://astx.com/2018-aacr-a-novel-erk1-2-inhibitor-has-potent-activity-in-kras-mutant-non-small-cell-lung-cancer-models-2/ 2024-02-12T15:53:13+00:00 monthly 0.2 https://astx.com/blakemore-et-al-organic-synthesis-provides-opportunities-to-transform-drug-discovery-nature-chemistry-vol-10-apr-2018-383-394-doi10-1038-s41557-018-0021-z/ 2021-09-28T13:17:36+00:00 monthly 0.2 https://astx.com/2018-aacr-development-of-a-potent-class-of-small-molecule-inhibitors-of-the-mdm2-p53-protein-protein-interaction/ 2024-02-12T15:58:18+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-2018/ 2018-05-11T20:56:17+00:00 monthly 0.2 https://astx.com/astexs-harren-jhoti-made-fellow-of-the-royal-society/ 2018-05-09T09:16:11+00:00 monthly 0.2 https://astx.com/bio-international-convention-2018/ 2018-05-09T11:19:34+00:00 monthly 0.2 https://astx.com/xue-et-al-map3k1-and-map2k4-mutations-are-associated-with-sensitivity-to-mek-inhibitors-in-multiple-cancer-models-cell-res-2018/ 2022-10-19T10:52:15+00:00 monthly 0.2 https://astx.com/2018-astx660-a-novel-non-peptidomimetic-antagonist-of-ciap1-2-and-xiap-potently-induces-tnf%ce%b1-dependent-apoptosis-in-cancer-cell-lines-and-inhibits-tumor-growth/ 2018-06-19T16:49:47+00:00 monthly 0.2 https://astx.com/eortc-nci-aacr/ 2018-07-18T23:19:56+00:00 monthly 0.2 https://astx.com/60th-ash-annual-meeting-exposition/ 2018-07-12T00:02:21+00:00 monthly 0.2 https://astx.com/agni-gavriilidou-et-al-advancing-life-sciences-rd-2018-online-application-of-native-esi-ms-to-characterize-interactions-between-compounds-derived-from-fragment-based-discovery-campaigns-and/ 2021-09-28T13:16:06+00:00 monthly 0.2 https://astx.com/heightman-et-al-fragment-based-discovery-of-a-potent-orally-bioavailable-inhibitor-that-modulates-the-phosphorylation-and-catalytic-activity-of-erk1-2-j-med-chem-2018-61-11-4978-4992-d/ 2021-09-28T13:14:40+00:00 monthly 0.2 https://astx.com/lebraud-et-al-a-highly-potent-clickable-probe-for-cellular-imaging-of-mdm2-and-assessing-dynamic-responses-to-mdm2-p53-inhibition-bioconjugate-chemistry-2018-ahead-of-print-doi-10-10/ 2021-09-28T13:13:32+00:00 monthly 0.2 https://astx.com/johnson-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2016-j-med-chem-2018-61-1774%e2%88%921784-doi-10-1021-acs-jmedchem-7b01298/ 2021-09-28T13:12:28+00:00 monthly 0.2 https://astx.com/ward-et-al-astx660-a-novel-non-peptidomimetic-antagonist-of-ciap1-2-and-xiap-potently-induces-tnf-%ce%b1-dependent-apoptosis-in-cancer-cell-lines-and-inhibits-tumor-growth-molecular/ 2021-09-28T13:11:26+00:00 monthly 0.2 https://astx.com/wright-et-al-engineering-and-purification-of-a-thermostable-high-yield-variant-of-pfcrt-the-plasmodium-falciparum-chloroquine-resistance-transporter-protein-expression-and-purification-141/ 2021-09-28T13:10:18+00:00 monthly 0.2 https://astx.com/price-et-al-fragment-based-drug-discovery-and-its-application-to-challenging-drug-targets-essays-in-biochemistry-2017-61-475-484-doi-10-1042-ebc20170029/ 2021-09-28T13:31:41+00:00 monthly 0.2 https://astx.com/lebraud-et-al-protein-degradation-a-validated-therapeutic-strategy-with-exciting-prospects-essays-in-biochemistry-2017-61-517-527-doi-10-1042-ebc20170030/ 2021-09-28T13:30:48+00:00 monthly 0.2 https://astx.com/sipthorp-et-al-includes-honorine-and-tom-heightman-visualization-of-endogenous-erk1-2-in-cells-with-a-bioorthogonal-covalent-probe-bioconjugate-chemistry-jun-2017-vol-28-no-6-pp-1677/ 2021-09-28T13:29:41+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-and-otsuka-announce-results-of-the-phase-3-astral-1-study-of-guadecitabine-sgi-110-in-treatment-naive-aml-patients-ineligible-to-receive-intense-induction-chemotherapy/ 2023-12-13T10:00:21+00:00 monthly 0.2 https://astx.com/johnson-et-al-a-fragment-derived-clinical-candidate-for-antagonism-of-x-linked-and-cellular-inhibitor-of-apoptosis-proteins-1-6-4-fluorophenylmethyl-5-hydroxymethyl-33-dimethyl-1h/ 2021-09-28T13:08:16+00:00 monthly 0.2 https://astx.com/jubb-et-al-cosmic-3d-provides-structural-perspectives-on-cancer-genetics-for-drug-discovery-nature-genetics-2018-doi-10-1038-s41588-018-0214-9/ 2021-09-28T13:07:01+00:00 monthly 0.2 https://astx.com/perera-tps-et-al-discovery-and-pharmacological-characterization-of-jnj-42756493-erdafitinib-a-functionally-selective-small-molecule-fgfr-family-inhibitor-mol-cancer-ther-201/ 2021-09-28T13:28:14+00:00 monthly 0.2 https://astx.com/lebraud-et-al-quantitation-of-erk1-2-inhibitor-cellular-target-occupancies-with-a-reversible-slow-off-rate-probe-chem-sci-october-2018-issue-37-doi-org-10-1039-c8sc02754d/ 2021-09-28T13:06:00+00:00 monthly 0.2 https://astx.com/sustic-et-al-a-role-for-the-unfolded-protein-response-stress-sensor-ern1-in-regulating-the-response-to-mek-inhibitors-in-kras-mutant-colon-cancers-genome-med-2018/ 2022-10-19T10:54:30+00:00 monthly 0.2 https://astx.com/2018-ash-long-term-results-of-a-randomized-phase-2-dose-response-study-of-guadecitabine-a-novel-subcutaneous-sc-hypomethylating-agent-hma-in-102-patients-with-intermediate-or-high-risk-myelodys/ 2024-02-12T16:29:43+00:00 monthly 0.2 https://astx.com/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ 2019-12-02T16:29:10+00:00 monthly 0.2 https://astx.com/milner-therapeutics-symposium-2019/ 2019-12-02T16:28:30+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-2019/ 2019-12-02T16:27:58+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-2/ 2019-12-02T16:27:25+00:00 monthly 0.2 https://astx.com/aruk-2019-alzheimers-research-uk-conference/ 2019-12-02T16:18:50+00:00 monthly 0.2 https://astx.com/tat-2019-international-congress-on-targeted-anticancer-therapies/ 2019-12-02T16:18:36+00:00 monthly 0.2 https://astx.com/grainger-et-al-enabling-synthesis-in-fragment-based-drug-discovery-by-reactivity-mapping-photoredox-mediated-cross-dehydrogenative-heteroarylation-of-cyclic-amines-chemical-science-2019-10-1039-c/ 2021-09-28T13:04:12+00:00 monthly 0.2 https://astx.com/ceska-et-al-cryo-em-in-drug-discovery-biochemical-society-transactions-2019-10-1042-bst20180267/ 2021-09-28T13:03:22+00:00 monthly 0.2 https://astx.com/ferraris-et-al-design-synthesis-and-pharmacological-evaluation-of-fluorinated-tetrahydrouridine-derivatives-as-inhibitors-of-cytidine-deaminase-journal-of-medicinal-chemistry-2014/ 2019-03-18T13:58:12+00:00 monthly 0.2 https://astx.com/oreilly-et-al-crystallographic-screening-using-ultra-low-molecular-weight-ligands-to-guide-drug-design-drug-discovery-today-2019-doi-org-10-1016-j-drudis-2019-03-009/ 2021-09-28T13:02:48+00:00 monthly 0.2 https://astx.com/deaton-et-al-the-discovery-of-quinoline-3-carboxamides-as-hematopoietic-prostaglandin-d-synthase-h-pgds-inhibitors-bioorganic/ 2021-09-28T13:02:13+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-celebrates-as-second-new-cancer-drug-receives-us-marketing-approval/ 2019-04-12T21:45:01+00:00 monthly 0.2 https://astx.com/heightman-et-al-structure-activity-and-structure-conformation-relationships-of-aryl-propionic-acid-inhibitors-of-the-kelch-like-ech-associated-protein-1-nuclear-factor-eryth/ 2021-09-28T13:01:18+00:00 monthly 0.2 https://astx.com/2019-mdsf-development-of-an-oral-hypomethylating-agent-hma-as-a-fixed-dose-combination-fdc-of-decitabine-and-cda-inhibitor-cedazuridine/ 2024-02-12T16:22:36+00:00 monthly 0.2 https://astx.com/2018-ebf-development-and-validation-of-an-lc-ms-ms-method-for-the-simultaneous-quantitation-of-cedazuridine-e7727-epimer-of-cedazuridine-and-decitabine-in-thu-stabilized-k2edta-human-plasma/ 2024-02-12T16:22:21+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-and-otsuka-announce-results-of-the-phase-3-ascertain-study-of-the-novel-oral-cedazuridine-and-decitabine-fixed-dose-combination-astx727-in-patients-with-myelodysplastic-syndrom/ 2020-05-06T20:09:04+00:00 monthly 0.2 https://astx.com/british-company-behind-groundbreaking-breast-cancer-treatment/ 2019-11-13T18:23:32+00:00 monthly 0.2 https://astx.com/taiho-oncology-announces-agreement-with-otsuka-to-commercialize-astex-pharmaceuticals-drug-candidates/ 2023-12-13T10:00:39+00:00 monthly 0.2 https://astx.com/2019-mdsf-long-term-survival-results-and-prognostic-factors-results-of-higher-risk-mds-and-cmml-treated-with-guadecitabine/ 2024-02-12T16:30:31+00:00 monthly 0.2 https://astx.com/2019-eha-characterization-of-a-novel-potent-small-molecule-mdm2-antagonist-which-activates-wild-type-p53-and-induces-apoptosis-in-aml/ 2024-02-12T15:56:38+00:00 monthly 0.2 https://astx.com/2019-eha-preliminary-results-of-astx660-a-novel-non-peptidomimetic-ciap1-2-and-xiap-antagonist-in-relapsed-refractory-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma/ 2024-02-12T15:47:40+00:00 monthly 0.2 https://astx.com/2019-eha-astx660-a-non-peptidomimetic-antagonist-of-ciap1-2-and-xiap-induces-apoptosis-in-t-cell-lymphoma-by-enhancing-immune-mediated-and-death-receptor-dependent-killing/ 2024-02-12T15:48:09+00:00 monthly 0.2 https://astx.com/2019-eha-results-of-astral-1-study-a-phase-3-randomized-trial-of-guadecitabine-g-vs-treatment-choice-tc-in-treatment-naive-acute-myeloid-leukemia-tn-aml-not-eligible-for-intensive-chemotherapy/ 2024-02-12T16:30:47+00:00 monthly 0.2 https://astx.com/2019-ictxv-nonclinical-development-of-cedazuridine-a-novel-cytidine-deaminase-inhibitor-for-use-in-combination-with-decitabine-to-enable-oral-administration-to-patients-with-myelodysplastic-syndrome/ 2024-02-12T16:24:12+00:00 monthly 0.2 https://astx.com/de-witte-effective-oral-hypomethylating-drugs-in-intermediate-risk-or-high-risk-myelodysplasia-a-breakthrough/ 2019-07-15T07:21:57+00:00 monthly 0.2 https://astx.com/savona-et-al-an-oral-fixed-dose-combination-of-decitabine-and-cedazuridine-in-myelodysplastic-syndromes-a-multicentre-open-label-dose-escalation-phase-1-study/ 2019-07-15T07:18:56+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-that-its-novel-oral-hypomethylating-agent-astx727-has-been-granted-orphan-drug-designation-for-the-treatment-of-myelodysplastic-syndromes-including-chronic-myelomonoc/ 2020-05-06T20:07:01+00:00 monthly 0.2 https://astx.com/murray-et-al-a-successful-collaboration-between-academia-biotech-and-pharma-led-to-discovery-of-erdafitinib-a-selective-fgfr-inhibitor-recently-approved-by-the-fda-medchemcomm/ 2021-09-28T13:00:27+00:00 monthly 0.2 https://astx.com/6966-2/ 2024-02-12T15:48:38+00:00 monthly 0.2 https://astx.com/2019-acop-a-semi-physiological-population-pharmacokinetic-model-developed-using-clinical-dose-escalation-and-dose-confirmation-data-for-an-oral-fixed-dose-combination-of-cda-inhibitor-cedazuridine-wi/ 2024-02-12T16:23:54+00:00 monthly 0.2 https://astx.com/2019-eortc-preliminary-results-of-astx660-a-novel-non-peptidomimetic-ciap1-2-and-xiap-antagonist-in-118-patients-with-solid-tumors-or-lymphoma/ 2024-02-12T15:48:49+00:00 monthly 0.2 https://astx.com/mortenson-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2017-journal-of-medicinal-chemistry-2019/ 2021-09-28T13:00:03+00:00 monthly 0.2 https://astx.com/a-novel-erk-inhibitor-has-potent-activity-in-nras-mutant-melanoma-cancer-models/ 2019-12-02T18:31:22+00:00 monthly 0.2 https://astx.com/dual-mechanism-erk1-2-inhibitors-exploit-a-distinct-binding-mode-to-block-phosphorylation-and-nuclear-accumulation-of-erk1-2/ 2024-02-12T15:53:34+00:00 monthly 0.2 https://astx.com/2019-ash-durable-remission-and-long-term-survival-in-relapsed-refractory-r-r-aml-patients-treated-with-guadecitabine-median-survival-not-reached-for-responders-after-long-term-follow-up-from-phase/ 2024-02-12T16:30:57+00:00 monthly 0.2 https://astx.com/2019-ash-results-from-a-global-randomized-phase-3-study-of-guadecitabine-g-vs-treatment-choice-tc-in-815-patients-with-treatment-naive-tn-aml-unfit-for-intensive-chemotherapy-ic-astral-1-stud/ 2024-02-12T16:31:12+00:00 monthly 0.2 https://astx.com/2019-ash-landmark-response-and-survival-analyses-from-102-mds-and-cmml-patients-treated-with-guadecitabine-in-a-phase-2-study-showing-that-maximum-response-and-survival-is-best-achieved-with-adequate/ 2024-02-12T16:31:25+00:00 monthly 0.2 https://astx.com/progression-free-survival-pfs-and-event-free-survival-efs-from-a-global-randomized-phase-3-study-of-guadecitabine-g-vs-treatment-choice-tc-in-815-patients-with-treatment-naive-tn-aml-unfit/ 2024-02-12T16:31:36+00:00 monthly 0.2 https://astx.com/ash-2019-landmark-response-and-survival-analyses-from-206-aml-patients-treated-with-guadecitabine-in-a-phase-2-study-demonstrate-the-importance-of-adequate-treatment-duration-to-maximize-response-and/ 2024-02-12T16:31:52+00:00 monthly 0.2 https://astx.com/2019-ash-pharmacokinetic-exposure-equivalence-and-preliminary-efficacy-and-safety-from-a-randomized-cross-over-phase-3-study-ascertain-study-of-an-oral-hypomethylating-agent-astx727-cedazuridine/ 2024-02-12T16:24:25+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-presents-topline-data-from-the-ascertain-phase-3-study-of-its-novel-oral-hypomethylating-agent-cedazuridine-and-decitabine-astx727-in-mds-and-cmml-at-the-american-society-of-h/ 2023-12-13T10:01:05+00:00 monthly 0.2 https://astx.com/2019-ash-oral-azacitidine-and-cedazuridine-approximate-azacitidine-efficacy-in-a-murine-model/ 2019-12-20T19:08:14+00:00 monthly 0.2 https://astx.com/ash-annual-meeting-exposition-2019/ 2024-01-08T14:56:07+00:00 monthly 0.2 https://astx.com/rathi-et-al-practical-high-quality-electrostatic-potential-surfaces-for-drug-discovery-using-a-graph-convolutional-deep-neural-network-journal-of-medicinal-chemistry-2020/ 2021-09-28T14:05:49+00:00 monthly 0.2 https://astx.com/dittmann-et-al-next-generation-hypomethylating-agent-sgi-110-primes-acute-myeloid-leukemia-cells-to-iap-antagonist-by-activating-extrinsic-and-intrinsic-apoptosis-pathways/ 2024-02-12T15:49:08+00:00 monthly 0.2 https://astx.com/mita-et-al-a-phase-1-study-of-astx660-an-antagonist-of-inhibitors-of-apoptosis-proteins-in-adults-with-advanced-cancers-or-lymphoma/ 2020-07-15T16:42:05+00:00 monthly 0.2 https://astx.com/osbourne-et-al-fragments-where-are-we-now-biochemical-society-transactions-2020/ 2021-09-28T14:04:59+00:00 monthly 0.2 https://astx.com/kidger-et-al-dual-mechanism-erk1-2-inhibitors-exploit-a-distinct-binding-mode-to-block-phosphorylation-and-nuclear-accumulation-of-erk1-2-mol-cancer-ther-2020kidger-et-al/ 2024-02-16T12:23:27+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-u-s-food-and-drug-administration-fda-acceptance-for-review-of-an-nda-for-the-combination-oral-hypomethylating-agent-cedazuridine-and-decitabine-astx727-or-oral-c-de/ 2023-12-13T10:01:17+00:00 monthly 0.2 https://astx.com/ye-et-al-astx660-an-antagonist-of-ciap1-2-and-xiap-increases-antigen-processing-machinery-and-can-enhance-radiation-induced-immunogenic-cell-death-in-preclinical-models-of-head-and-neck-cancer/ 2020-07-15T16:33:17+00:00 monthly 0.2 https://astx.com/saur-et-al-fragment-based-drug-discovery-using-cryo-em-drug-discovery-today-2020/ 2021-09-28T12:56:59+00:00 monthly 0.2 https://astx.com/garcia-manero-et-al-oral-cedazuridine-decitabine-a-phase-2-pharmacokinetic-pharmacodynamic-randomized-crossover-study-in-mds-and-cmml/ 2020-04-15T18:54:28+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-2020/ 2020-03-26T21:18:04+00:00 monthly 0.2 https://astx.com/2020-ramsey-et-al-oral-azacitidine-and-cedazuridine-approximate-parenteral-azacitidine-efficacy-in-murine-model/ 2020-05-12T06:39:05+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-2/ 2020-03-26T21:23:08+00:00 monthly 0.2 https://astx.com/coyle-et-al-applied-biophysical-methods-in-fragment-based-drug-discovery-slas-discovery-2020/ 2021-09-28T14:04:34+00:00 monthly 0.2 https://astx.com/erlanson-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2018-journal-of-medicinal-chemistry-2020/ 2021-09-28T12:53:36+00:00 monthly 0.2 https://astx.com/2020-eha-comparative-results-of-azacitidine-and-decitabine-from-a-large-prospective-phase-3-study-in-treatment-naive-acute-myeloid-leukemia-tn-aml-not-eligible-for-intensive-chemotherapy/ 2020-06-25T04:54:57+00:00 monthly 0.2 https://astx.com/2020-eha-astx295-a-novel-small-molecule-mdm2-antagonist-demonstrates-potent-activity-in-aml-in-combination-with-decitabine/ 2024-02-12T15:56:18+00:00 monthly 0.2 https://astx.com/2020-eha-characterization-of-astx660-an-antagonist-of-ciap1-2-and-xiap-in-mouse-models-of-t-cell-lymphoma/ 2024-02-12T15:49:27+00:00 monthly 0.2 https://astx.com/2017-eortc-characterisation-of-a-novel-erk1-2-inhibitor-which-modulates-the-phosphorylation-and-catalytic-activity-of-erk1-2/ 2024-02-12T16:05:59+00:00 monthly 0.2 https://astx.com/2018-eortc-a-novel-erk1-2-inhibitor-has-potent-activity-in-nras-mutant-melanoma-cancer-models/ 2024-02-12T15:58:37+00:00 monthly 0.2 https://astx.com/2019-ad-pd-discovering-small-molecule-modulators-of-autophagy-for-neurodegeneration/ 2024-02-12T15:58:50+00:00 monthly 0.2 https://astx.com/2020-aacr-different-pharmacodynamic-profiles-of-erk1-2-inhibition-can-elicit-comparable-anti-tumor-activity/ 2024-02-12T15:59:20+00:00 monthly 0.2 https://astx.com/2020-aacr-astx660-a-non-peptidomimetic-antagonist-of-ciap1-2-and-xiap-promotes-an-anti-tumor-immune-response-in-pre-clinical-models-of-t-cell-lymphoma/ 2024-02-12T15:49:46+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-taiho-oncology-and-otsuka-pharmaceutical-announce-fda-and-health-canada-approval-of-inqovi-decitabine-and-cedazuridine-tablets-oral-hypomethylating-agent-hma-therapy/ 2023-12-13T10:01:36+00:00 monthly 0.2 https://astx.com/design-and-synthesis-of-56-shape-diverse-3d-fragments/ 2021-09-28T12:53:03+00:00 monthly 0.2 https://astx.com/2020-aacr-fragment-based-drug-discovery-to-identify-small-molecule-allosteric-inhibitors-of-shp2/ 2024-02-12T15:59:39+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announces-that-tolinapant-astx660-a-novel-antagonist-of-cellular-and-x-linked-inhibitors-of-apoptosis-proteins-has-been-granted-orphan-drug-designation-for-the-treatment-of-t/ 2023-12-13T10:01:47+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-and-md-anderson-announce-strategic-collaboration-to-accelerate-clinical-evaluation-of-therapies-for-patients-with-leukemia/ 2023-12-13T10:02:01+00:00 monthly 0.2 https://astx.com/cadilla-et-al-the-exploration-of-aza-quinolines-as-hematopoietic-prostaglandin-d-synthase-h-pgds-inhibitors-with-low-brain-exposure-bioorganic-medicinal-chemistry-2020/ 2021-09-28T12:52:57+00:00 monthly 0.2 https://astx.com/astex-and-otsuka-announce-results-of-phase-3-astral-2-and-astral-3-studies-of-guadecitabine-sgi-110-in-patients-with-previously-treated-acute-myeloid-leukemia-aml-and-myelodysplastic-syndromes-or/ 2023-12-13T10:02:28+00:00 monthly 0.2 https://astx.com/the-clinical-candidate-astx029-is-a-novel-dual-mechanism-erk1-2-inhibitor-and-has-potent-activity-in-mapk-activated-cancer-cell-lines-and-in-vivo-tumor-models/ 2024-02-12T15:53:54+00:00 monthly 0.2 https://astx.com/combined-inhibition-of-shp2-and-erk-enhances-anti-tumor-effects-in-preclinical-models/ 2024-02-12T15:54:10+00:00 monthly 0.2 https://astx.com/identification-of-potent-small-molecule-allosteric-inhibitors-of-shp2/ 2024-02-12T16:00:14+00:00 monthly 0.2 https://astx.com/the-non-peptidomimetic-ciap1-2-and-xiap-antagonist-tolinapant-promotes-an-anti-tumour-immune-response-in-t-cell-lymphoma/ 2024-02-12T15:50:04+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-expands-clinical-evaluation-of-oral-decitabine-and-cedazuridine-tablets-through-new-cooperative-research-and-development-agreement-crada-with-the-u-s-national-cancer-institute/ 2023-12-13T10:02:46+00:00 monthly 0.2 https://astx.com/32nd-eortc-nci-aacr-symposium/ 2023-12-14T17:57:08+00:00 monthly 0.2 https://astx.com/jahnke-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2019-journal-of-medicinal-chemistry-2020/ 2021-09-28T12:52:49+00:00 monthly 0.2 https://astx.com/ash-2020-abstract-1230_savona/ 2020-12-05T15:02:32+00:00 monthly 0.2 https://astx.com/ash-2020-abstract-1037_zeidan/ 2020-12-05T15:04:37+00:00 monthly 0.2 https://astx.com/2020-ash-anti-tumor-activity-of-astx029-a-dual-mechanism-inhibitor-of-erk1-2-in-preclinical-aml-models/ 2024-02-12T15:54:23+00:00 monthly 0.2 https://astx.com/holvey-et-al-identifying-and-developing-small-molecule-inhibitors-of-protein-protein-interactions-rsc-publications-2020/ 2021-11-05T13:51:41+00:00 monthly 0.2 https://astx.com/ash-annual-meeting-2/ 2020-08-10T18:42:17+00:00 monthly 0.2 https://astx.com/st-denis-et-al-fragment-based-drug-discovery-opportunities-for-organic-synthesis-rsc-medicinal-chemistry-2020/ 2021-09-28T12:52:09+00:00 monthly 0.2 https://astx.com/grainger-et-al-a-perspective-on-the-analytical-challenges-encountered-in-high-throughput-experimentation-organic-process-research-and-development-2021/ 2021-09-28T12:54:59+00:00 monthly 0.2 https://astx.com/brain-et-al-the-discovery-of-kisqali-ribociclib-a-cdk4-6-inhibitor-for-the-treatment-of-hr-her2%e2%88%92-advanced-breast-cancer/ 2021-10-27T09:10:00+00:00 monthly 0.2 https://astx.com/sethi-et-al-leveraging-omic-features-with-f3uter-enables-identification-of-unannotated-3utrs-for-synaptic-genes/ 2022-04-27T10:29:42+00:00 monthly 0.2 https://astx.com/chessari-at-al-structure-based-design-of-potent-and-orally-active-isoindolinone-inhibitors-of-mdm2-p53-protein-protein-interaction/ 2024-02-16T12:25:35+00:00 monthly 0.2 https://astx.com/nccn-announces-projects-to-study-oral-decitabine-and-cedazuridine-in-collaboration-with-taiho-oncology/ 2023-12-13T10:03:12+00:00 monthly 0.2 https://astx.com/2021-aacr-immune-modulation-by-the-dual-mechanism-erk-inhibitor-astx029-in-mapk-activated-tumor-models/ 2024-02-12T15:54:40+00:00 monthly 0.2 https://astx.com/2021-aacr-a-first-in-human-phase-1-study-of-astx029-a-dual-mechanism-inhibitor-of-erk1-2-in-relapsed-refractory-solid-tumors/ 2024-02-12T15:55:06+00:00 monthly 0.2 https://astx.com/poon-et-al-the-role-of-sqstm1-p62-in-mitochondrial-function-and-clearance-in-human-cortical-neurons-stem-cell-reports-2021/ 2022-10-19T10:49:53+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-3/ 2021-04-20T22:30:48+00:00 monthly 0.2 https://astx.com/almeida-et-al-nmr-reporter-assays-for-the-quantification-of-weak-affinity-receptor-ligand-interactions-slas-discovery-april-2021/ 2021-09-28T12:47:54+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-3/ 2021-04-20T22:34:34+00:00 monthly 0.2 https://astx.com/munck-et-al-astx029-a-novel-dual-mechanism-erk-inhibitor-modulates-both-the-phosphorylation-and-catalytic-activity-of-erk/ 2021-08-17T14:50:11+00:00 monthly 0.2 https://astx.com/tom-d-heightman-et-al-discovery-of-astx029-a-clinical-candidate-which-modulates-the-phosphorylation-and-catalytic-activity-of-erk1-2-acs-publications-2021/ 2021-08-17T14:46:04+00:00 monthly 0.2 https://astx.com/chessari-et-al-c-h-functionalisation-tolerant-to-polar-groups-could-transform-fragment-based-drug-discovery-fbdd-chemical-science-2021/ 2021-09-28T14:09:18+00:00 monthly 0.2 https://astx.com/2021-blood-virtual-congress-clinical-efficacy-and-safety-of-oral-decitabine-cedazuridine-in-133-patients-with-myelodysplastic-syndromes-mds-and-chronic-myelomonocytic-leukemia-cmml/ 2021-09-20T15:38:05+00:00 monthly 0.2 https://astx.com/2021-virtual-16th-mds-conference-prolonged-survival-observed-in-133-mds-patients-treated-with-oral-decitabine-cedazuridine/ 2021-09-23T14:10:25+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-presents-overall-survival-data-from-ascertain-phase-3-study-of-oral-hypomethylating-agent-inqovi-decitabine-and-cedazuridine-in-mds-and-cmml-at-international-congress-on/ 2023-12-13T10:03:31+00:00 monthly 0.2 https://astx.com/9175-2/ 2021-10-25T13:59:20+00:00 monthly 0.2 https://astx.com/norton-et-al-fragment-guided-discovery-of-pyrazole-carboxylic-acid-inhibitors-of-the-kelch-like-ech-associated-protein-1-nuclear-factor-erythroid-2-related-factor-2-keap1nrf2-protein/ 2021-11-05T13:43:49+00:00 monthly 0.2 https://astx.com/ash-2021-a-phase-1-study-evaluating-astx727-decitabine-and-cedazuridine-and-venetoclax-in-combination-therapy-in-newly-diagnosed-aml-patients-unfit-for-intensive-induction-chemotherapy/ 2021-12-11T23:02:46+00:00 monthly 0.2 https://astx.com/2021-ash-oral-decitabine-cedazuridine-in-patients-with-lower-risk-myelodysplastic-syndrome-a-longer-term-follow-up-of-from-the-ascertain-study/ 2021-12-11T23:12:42+00:00 monthly 0.2 https://astx.com/2021-ash-results-from-a-global-randomized-phase-3-study-of-guadecitabine-g-vs-treatment-choice-tc-in-302-patients-with-relapsed-or-refractory-r-r-acute-myeloid-leukemia-after-intensive-chemothe/ 2024-02-12T16:32:04+00:00 monthly 0.2 https://astx.com/2021-ash-combining-the-iap-antagonist-tolinapant-with-a-dna-hypomethylating-agent-enhances-immunogenic-cell-death-in-preclinical-models-of-t-cell-lymphoma/ 2024-02-12T15:50:23+00:00 monthly 0.2 https://astx.com/2021-ash-efficacy-of-oral-decitabine-cedazuridine-astx727-in-the-cmml-subpopulation-from-ascertain-phase-3-study/ 2021-12-13T14:31:42+00:00 monthly 0.2 https://astx.com/63rd-ash-annual-meeting-exposition/ 2022-02-08T23:00:07+00:00 monthly 0.2 https://astx.com/rees-medicines-for-millions-of-patients-rsc-medicinal-chemistry-jan-2022/ 2022-02-22T08:47:22+00:00 monthly 0.2 https://astx.com/oral-decitabine-and-cedazuridine-astx727-granted-orphan-drug-designation-odd-by-the-european-commission-for-the-treatment-of-acute-myeloid-leukemia-aml/ 2023-12-13T10:03:42+00:00 monthly 0.2 https://astx.com/2021-eortc-treatment-with-the-dual-mechanism-erk-inhibitor-astx029-alters-myeloid-cell-differentiation/ 2024-02-12T15:55:34+00:00 monthly 0.2 https://astx.com/2021-ash-erk1-2-inhibition-overcomes-resistance-in-acute-myeloid-leukemia-aml-and-alters-mitochondrial-dynamics/ 2024-02-12T16:00:43+00:00 monthly 0.2 https://astx.com/de-esch-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2020-j-med-chem-2022/ 2022-03-24T09:25:39+00:00 monthly 0.2 https://astx.com/poelking-et-al-meaningful-machine-learning-models-and-machine-learned-pharmacophores-from-fragment-screening-campaigns-arxiv-2022/ 2022-10-19T10:42:51+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-2022/ 2022-01-03T12:15:14+00:00 monthly 0.2 https://astx.com/cons-et-al-electrostatic-complementarity-in-structure-based-drug-design-j-med-chem-2022/ 2022-05-06T08:43:04+00:00 monthly 0.2 https://astx.com/astex-announces-that-the-phase-3-ascertain-acute-myeloid-leukemia-aml-clinical-study-of-oral-hypomethylating-agent-decitabine-and-cedazuridine-fixed-dose-combination-astx727-or-dec-c-met-the-tri/ 2023-12-13T10:04:03+00:00 monthly 0.2 https://astx.com/2022-asco-a-first-in-human-phase-1-study-of-astx029-a-dual-mechanism-inhibitor-of-erk1-2-in-relapsed-refractory-solid-tumors/ 2024-02-12T15:55:52+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-2022/ 2022-05-31T18:14:58+00:00 monthly 0.2 https://astx.com/2022-eha-combining-the-iap-antagonist-tolinapant-with-a-dna-hypomethylating-agent-enhances-anti-tumour-mechanisms-in-preclinical-models-of-t-cell-lymphoma/ 2024-02-12T15:50:46+00:00 monthly 0.2 https://astx.com/2022-eha-guadecitabine-sgi-110-vs-treatment-choice-tc-in-relapsed-refractoryr-r-myelodysplastic-syndrome-mds-results-of-a-global-randomized-phase-3-study/ 2022-06-11T21:47:33+00:00 monthly 0.2 https://astx.com/2022-eha-pharmacokinetic-exposure-equivalence-and-preliminary-efficacy-and-safety-from-a-randomized-crossover-phase-3-study-of-an-oral-hypomethylating-agent-astx727-dec-c-compared-to-iv-decitabin/ 2022-06-11T22:25:23+00:00 monthly 0.2 https://astx.com/eha-congress-2022/ 2022-01-03T12:18:37+00:00 monthly 0.2 https://astx.com/2022-eha-preliminary-analysis-of-the-phase-ii-study-using-tolinapant-astx660-monotherapy-in-98-peripheral-t-cell-lymphoma-and-51-cutaneous-t-cell-lymphoma-subjects-with-relapsed-refractory-disease/ 2024-02-12T15:51:01+00:00 monthly 0.2 https://astx.com/2022-tclf-trials-in-progress-a-phase-1-2-open-label-study-of-the-safety-pharmacokinetics-pharmacodynamics-and-preliminary-activity-of-tolinapant-in-combination-with-oral-decitabine-cedazuridine/ 2024-02-12T15:51:14+00:00 monthly 0.2 https://astx.com/2022-tclf-preliminary-analysis-of-the-phase-ii-study-using-tolinapant-astx660-monotherapy-in-98-peripheral-t-cell-lymphoma-and-51-cutaneous-t-cell-lymphoma-subjects-with-relapsed-refractory-disease/ 2024-02-12T15:51:25+00:00 monthly 0.2 https://astx.com/poelking-et-al-benchml-an-extensible-pipelining-framework-for-benchmarking-representations-of-materials-and-molecules-at-scale-mach-learn-sci-technol-2022/ 2022-08-02T15:16:47+00:00 monthly 0.2 https://astx.com/pomberger-et-al-the-effect-of-chemical-representation-on-active-machine-learning-towards-closed-loop-optimization-react-chem-eng-2022/ 2022-08-02T15:17:20+00:00 monthly 0.2 https://astx.com/kakade-et-al-mapping-of-a-n-terminal-%ce%b1-helix-domain-required-for-human-pink1-stabilization-serine228-autophosphorylation-and-activation-in-cells-open-biol-2022/ 2022-08-02T15:16:37+00:00 monthly 0.2 https://astx.com/martins-et-al-a-validated-liquid-chromatography-tandem-mass-spectroscopy-method-for-the-quantification-of-tolinapant-in-human-plasma-anal-sci-adv-2022/ 2022-08-02T15:16:18+00:00 monthly 0.2 https://astx.com/izsak-et-al-quantum-computing-in-pharma-a-multilayer-embedding-approach-for-near-future-applications-j-comput-chem-2022/ 2022-08-04T09:20:04+00:00 monthly 0.2 https://astx.com/priyanka-et-al-mitoxantrone-stacking-does-not-define-the-active-or-inactive-state-of-usp15-catalytic-domain-j-struct-biol-2022/ 2022-08-04T09:20:24+00:00 monthly 0.2 https://astx.com/astex-wins-3-awards-for-participating-in-the-bioindustry-association-bia-850-global-challenge-for-kidney-research-uk-2022/ 2022-08-04T09:11:44+00:00 monthly 0.2 https://astx.com/european-medicines-agency-commences-review-of-oral-fixed-dose-combination-of-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-acute-myeloid-leukemia/ 2023-12-13T10:04:21+00:00 monthly 0.2 https://astx.com/da-silva-junior-et-al-growth-vector-elaboration-of-fragments-regioselective-functionalization-of-5-hydroxy-6-azaindazole-and-3-hydroxy-26-naphthyridine-org-biomol-chem-2022/ 2022-10-19T10:37:36+00:00 monthly 0.2 https://astx.com/tamanini-et-al-fragment-based-discovery-of-a-novel-brain-penetrant-orally-active-hdac2-inhibitor-acs-med-chem-lett-2022/ 2022-10-19T10:36:43+00:00 monthly 0.2 https://astx.com/st-denis-et-al-x-ray-screening-of-an-electrophilic-fragment-library-and-application-toward-the-development-of-a-novel-erk-1-2-covalent-inhibitor-j-med-chem-2022/ 2022-10-19T10:37:03+00:00 monthly 0.2 https://astx.com/lea-et-al-cryo-em-diversifies-current-opinion-in-structural-biology-2022/ 2022-10-19T10:37:57+00:00 monthly 0.2 https://astx.com/2022-acop-a-population-pharmacokinetic-model-of-tolinapant-in-subjects-with-advanced-solid-tumors-and-lymphomas/ 2024-02-12T15:51:41+00:00 monthly 0.2 https://astx.com/blunt-et-al-perspective-on-the-current-state-of-the-art-of-quantum-computing-for-drug-discovery-applications-j-chem-theory-comput-2022/ 2022-12-23T13:46:17+00:00 monthly 0.2 https://astx.com/2022-eha-combining-the-iap-antagonist-tolinapant-with-a-dna-hypomethylating-agent-enhances-anti-tumour-mechanisms-in-preclinical-models-of-t-cell-lymphoma-2/ 2024-02-12T16:00:58+00:00 monthly 0.2 https://astx.com/jones-et-al-exploration-of-piperidine-3d-fragment-chemical-space-synthesis-and-3d-shape-analysis-of-fragments-derived-from-20-regio-and-diastereoisomers-of-methyl-substituted-pipecolinate/ 2022-11-25T09:11:05+00:00 monthly 0.2 https://astx.com/chan-et-al-a-multilevel-generative-framework-with-hierarchical-self-contrasting-for-bias-control-and-transparency-in-structure-based-ligand-design-nat-mach-intell-2022/ 2022-12-23T14:34:18+00:00 monthly 0.2 https://astx.com/2022-ash-phase-2-study-of-oral-decitabine-cedazuridine-in-combination-with-magrolimab-for-previously-untreated-subjects-with-intermediate-to-very-high-risk-myelodysplastic-syndromes-mds/ 2022-12-12T20:28:55+00:00 monthly 0.2 https://astx.com/2022-ash-astx727-03-phase-1-study-evaluating-oral-decitabine-cedazuridine-astx727-low-dose-ld-in-lower-risk-myelodysplastic-syndromes-lr-mds-patients/ 2022-12-12T20:45:26+00:00 monthly 0.2 https://astx.com/taiho-oncology-and-astex-pharmaceuticals-present-overall-survival-data-for-oral-decitabine-and-cedazuridine-inqovi-astx727-in-patients-with-mds-and-cmml-harboring-tp53-mutations-at-64th-ash-a/ 2023-12-13T10:04:30+00:00 monthly 0.2 https://astx.com/2022-ash-prolonged-survival-in-bi-allelic-tp53-mutated-tp53mut-mds-subjects-treated-with-oral-decitabine-cedazuridine-in-the-ascertain-trial-astx727-02/ 2022-12-12T23:36:53+00:00 monthly 0.2 https://astx.com/ash-annual-meeting-2022/ 2023-01-05T00:36:02+00:00 monthly 0.2 https://astx.com/martins-et-al-a-commentary-on-the-use-of-pharmacoenhancers-in-the-pharmaceutical-industry-and-the-implication-for-dmpk-drug-discovery-strategies-xenobiotica-2022/ 2022-12-23T13:43:19+00:00 monthly 0.2 https://astx.com/astex-co-founder-and-ceo-harren-jhoti-awarded-obe-in-the-kings-new-year-honours/ 2022-12-31T08:47:42+00:00 monthly 0.2 https://astx.com/walsh-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2021-j-med-chem-2023/ 2023-01-13T14:28:03+00:00 monthly 0.2 https://astx.com/rees-et-al-introduction-to-the-themed-collection-on-fragment-based-drug-discovery-rsc-med-chem-2022/ 2023-01-18T09:19:54+00:00 monthly 0.2 https://astx.com/astex-and-cardiff-university-medicines-discovery-institute-announce-new-drug-discovery-collaboration-on-neurodegenerative-diseases/ 2023-02-13T09:00:12+00:00 monthly 0.2 https://astx.com/shibuya-et-al-smac-mimetics-synergistically-cooperate-with-hdac-inhibitors-enhancing-tnf-%ce%b1-autocrine-signaling-cancers-2023/ 2023-03-16T14:08:16+00:00 monthly 0.2 https://astx.com/wu-et-al-systematic-construction-of-progressively-larger-capsules-from-a-fivefold-linking-pyrrole-based-subcomponent-nature-synthesis-2023/ 2023-04-13T11:41:14+00:00 monthly 0.2 https://astx.com/taylor-et-al-a-brief-introduction-to-chemical-reaction-optimization-chem-rev-2023/ 2023-04-13T11:49:29+00:00 monthly 0.2 https://astx.com/taylor-et-al-accelerated-chemical-reaction-optimization-using-multi-task-learning-acs-cent-sci-2023/ 2023-04-20T10:24:53+00:00 monthly 0.2 https://astx.com/morado-et-al-does-a-machine-learned-potential-perform-better-than-an-optimally-tuned-traditional-force-field-a-case-study-on-fluorohydrins-j-chem-inf-model-2023/ 2023-06-14T08:25:13+00:00 monthly 0.2 https://astx.com/aacr-annual-meeting-2023/ 2023-01-05T00:49:04+00:00 monthly 0.2 https://astx.com/acute-leukemia-forum/ 2023-03-27T13:04:55+00:00 monthly 0.2 https://astx.com/2023-intl-mds-congress-phase-2-study-of-oral-decitabine-cedazuridine-in-combination-with-magrolimab-for-previously-untreated-subjects-with-intermediate-to-very-high-risk-myelodysplastic-syndromes-md/ 2023-05-03T12:37:10+00:00 monthly 0.2 https://astx.com/2023-intl-congress-on-mds-phase-1-study-evaluating-low-dose-ld-oral-decitabine-cedazuridine-astx727-in-lower-risk-myelodysplastic-syndromes-lr-mds-patients/ 2023-05-03T13:12:11+00:00 monthly 0.2 https://astx.com/2023-int-congress-on-mds-randomized-phase-2-study-to-assess-safety-and-efficacy-of-low-dose-ld-oral-decitabine-cedazuridine-astx727-in-lower-risk-myelodysplastic-syndromes-lr-mds-patients-int/ 2023-05-03T13:12:26+00:00 monthly 0.2 https://astx.com/2023-int-congress-on-mds-efficacy-and-safety-of-oral-decitabine-cedazuridine-astx27-in-the-cmml-subpopulation-from-phase-2-and-ascertain-phase-3-studies/ 2023-05-03T13:48:22+00:00 monthly 0.2 https://astx.com/10336-2/ 2023-01-05T00:54:08+00:00 monthly 0.2 https://astx.com/wu-et-al-a-diverse-array-of-large-capsules-transform-in-response-to-stimuli-j-am-chem-soc-2023/ 2023-06-14T08:28:12+00:00 monthly 0.2 https://astx.com/asco-annual-meeting-2023/ 2023-01-05T01:29:00+00:00 monthly 0.2 https://astx.com/eha-congress/ 2023-03-27T13:03:27+00:00 monthly 0.2 https://astx.com/17th-international-conference-on-malignant-lymphoma-icml/ 2023-03-27T13:12:20+00:00 monthly 0.2 https://astx.com/2023-eha-randomized-phase-1-2-study-to-assess-safety-and-efficacy-of-low-dose-ld-oral-decitabine-cedazuridine-astx727-in-lower-risk-myelodysplastic-syndromes-lr-mds-patients-interim-safety-ana/ 2023-06-14T15:47:43+00:00 monthly 0.2 https://astx.com/2023-eha-efficacy-and-safety-of-oral-decitabine-cedazuridine-astx727-in-the-cmml-subpopulation-from-phase-2-and-ascertain-phase-3-studies/ 2023-06-14T15:48:34+00:00 monthly 0.2 https://astx.com/astex-expands-drug-discovery-collaboration-with-msd/ 2024-03-26T14:33:23+00:00 monthly 0.2 https://astx.com/2023-soho-efficacy-and-safety-of-oral-decitabine-cedazuridine-astx727-in-the-cmml-subpopulation-from-phase-2-and-ascertain-phase-3-studies/ 2023-09-07T12:51:39+00:00 monthly 0.2 https://astx.com/10700-2/ 2023-09-07T12:54:07+00:00 monthly 0.2 https://astx.com/otsuka-and-astex-announce-that-the-european-commission-has-approved-inaqovi-oral-decitabine-and-cedazuridine-for-the-treatment-of-adults-with-newly-diagnosed-acute-myeloid-leukaemia/ 2023-12-13T10:04:40+00:00 monthly 0.2 https://astx.com/2023-aacr-nci-eortc-poster-identifying-sensitive-patient-populations-for-cdk7-inhibitors-using-cell-panel-screens-and-bioinformatic-approaches/ 2025-01-09T17:51:21+00:00 monthly 0.2 https://astx.com/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/ 2023-03-27T13:11:13+00:00 monthly 0.2 https://astx.com/astex-cso-david-rees-honoured-as-a-hero-of-chemistry-by-the-american-chemical-society/ 2023-11-20T10:02:34+00:00 monthly 0.2 https://astx.com/esh-6th-international-conference-on-acute-myeloid-leukaemia-molecular-and-translational-advances-in-biology-and-treatment/ 2023-03-27T13:13:04+00:00 monthly 0.2 https://astx.com/aiho-oncology-and-astex-pharmaceuticals-announce-data-presentations-at-the-65th-ash-annual-meeting/ 2023-12-13T09:56:11+00:00 monthly 0.2 https://astx.com/third-success-from-astex-drug-discovery-pharma-collaboration-and-licence-agreements-as-astrazeneca-receives-us-marketing-approval-for-cancer-drug-truqap-capivasertib/ 2023-11-20T10:07:22+00:00 monthly 0.2 https://astx.com/townley-et-al-enabling-synthesis-in-fragment-based-drug-discovery-fbdd-microscale-high-throughput-optimisation-of-the-medicinal-chemists-toolbox-reactions-rsc-med-chem-2023/ 2024-06-06T11:05:28+00:00 monthly 0.2 https://astx.com/ash-annual-meeting-3/ 2023-03-27T13:25:35+00:00 monthly 0.2 https://astx.com/woodhead-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2022-j-med-chem-2024/ 2024-03-26T14:33:05+00:00 monthly 0.2 https://astx.com/eortc-poster-2022-low-skp2-expression-is-predictive-of-sensitivity-to-an-mdm2-antagonist-in-p53-wild-type-aml/ 2024-02-16T12:32:15+00:00 monthly 0.2 https://astx.com/ena-poster-2022-a-combination-vertical-inhibition-approach-with-inhibitors-of-shp2-and-erk-provides-improved-activity-in-kras-mutant-pancreatic-and-colorectal-cancer-models/ 2024-03-26T14:32:55+00:00 monthly 0.2 https://astx.com/day-et-al-fragment-based-discovery-of-allosteric-inhibitors-of-sh2-domain-containing-protein-tyrosine-phosphatase-2-shp2-j-med-chem-2024/ 2024-03-26T14:32:45+00:00 monthly 0.2 https://astx.com/henderikx-et-al-vitrojet-new-features-and-case-studies-structural-biology-2024/ 2024-03-26T14:37:05+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announce-key-data-presentations-at-the-american-association-for-cancer-research-aacr-2024-annual-meeting/ 2024-10-18T15:25:54+00:00 monthly 0.2 https://astx.com/2024-aacr-poster-targeting-the-mdm2-p53-interaction-time-and-concentration-dependent-studies-in-tumor-and-normal-human-bone-marrow-cells-reveal-strategies-for-an-enhanced-therapeutic-index/ 2024-04-23T13:20:33+00:00 monthly 0.2 https://astx.com/2024-aacr-poster-phase-1-study-of-mdm2-antagonist-astx295-in-patients-with-solid-tumors-with-wild-type-tp53/ 2024-04-23T13:20:24+00:00 monthly 0.2 https://astx.com/2024-aacr-poster-identification-of-biomarkers-of-response-to-mdm2-inhibition-in-solid-tumours-using-computational-multi-omics-approaches/ 2024-04-23T13:22:25+00:00 monthly 0.2 https://astx.com/2024-aacr-oral-discovery-of-astx295-a-potent-next-generation-small-molecule-antagonist-of-mdm2-with-differentiated-pharmacokinetic-profile-from-concept-to-clinic/ 2024-10-23T16:13:11+00:00 monthly 0.2 https://astx.com/dean-et-al-alkene-13-difluorination-via-transient-oxonium-intermediates-angewandte-chemie-2024/ 2024-07-12T14:36:51+00:00 monthly 0.2 https://astx.com/ward-et-al-epigenetic-priming-by-hypomethylation-enhances-the-immunogenic-potential-of-tolinapant-in-t-cell-lymphoma-cancer-research-communications-2024/ 2024-06-07T07:55:43+00:00 monthly 0.2 https://astx.com/sanchez-garcia-et-al-cesped-a-benchmark-for-supervised-particle-pose-estimation-in-cryo-em-physical-review-research-2024/ 2024-07-12T14:43:53+00:00 monthly 0.2 https://astx.com/2023-ash-poster-epigenetic-priming-by-hypomethylation-enhances-the-immunogenic-potential-of-tolinapant-in-t-cell-lymphoma/ 2024-06-06T13:09:19+00:00 monthly 0.2 https://astx.com/mukherjee-et-al-protein-engineering-enables-a-soakable-crystal-form-of-human-cdk7-primed-for-high-throughput-crystallography-and-structure-based-drug-design-structure-2024/ 2024-07-12T14:30:48+00:00 monthly 0.2 https://astx.com/ma-et-al-discovery-of-mk-1084-an-orally-bioavailable-and-low-dose-krasg12c-inhibitor-j-med-chem-2024/ 2024-07-12T14:34:01+00:00 monthly 0.2 https://astx.com/gustavvson-et-al-the-annotation-of-gba1-has-been-concealed-by-its-protein-coding-pseudogene-gbap1-science-advances-2024/ 2024-07-12T14:32:26+00:00 monthly 0.2 https://astx.com/palmer-et-al-fragment-based-discovery-of-a-series-of-allosteric-binding-site-modulators-of-%ce%b2-glucocerebrosidase-j-med-che-2024/ 2024-07-15T08:50:02+00:00 monthly 0.2 https://astx.com/fragment-based-lead-discovery-conference-fbld-2024/ 2024-06-06T11:14:28+00:00 monthly 0.2 https://astx.com/2024-esmo-poster-activity-of-erk1-2-inhibitor-astx029-in-patients-with-gynecological-malignancies-harboring-genomic-alterations-in-the-mapk-pathway/ 2024-10-23T16:14:54+00:00 monthly 0.2 https://astx.com/astex-pharmaceuticals-announce-key-data-presentations-at-the-36th-eortc-nci-aacr-symposium/ 2024-10-21T08:00:07+00:00 monthly 0.2 https://astx.com/ramos-et-al-proteome-wide-cetsa-reveals-diverse-apoptosis-inducing-mechanisms-converging-on-an-initial-apoptosis-effector-stage-at-the-nuclear-periphery-cell-reports-2024/ 2024-11-19T11:56:31+00:00 monthly 0.2 https://astx.com/2024-ena-poster-identification-of-biomarkers-predictive-of-response-to-astx295-a-next-generation-mdm2-antagonist-in-solid-tumors-carrying-wild-type-p53/ 2024-10-23T16:14:43+00:00 monthly 0.2 https://astx.com/2024-ena-poster-targeting-the-catalytic-hat-domain-of-cbp-p300-for-the-treatment-of-hormone-dependent-breast-and-prostate-cancers/ 2024-10-23T16:14:32+00:00 monthly 0.2 https://astx.com/2024-ena-poster-a-novel-small-molecule-cbp-p300-hat-domain-inhibitor-demonstrates-potent-in-vivo-activity-and-a-favourable-safety-profile-in-preclinical-species/ 2025-04-30T18:02:27+00:00 monthly 0.2 https://astx.com/2024-ena-poster-pulsatile-induction-of-the-p53-pathway-by-mdm2-antagonist-astx295-shows-an-enhanced-therapeutic-index-in-vivo/ 2024-10-24T16:22:37+00:00 monthly 0.2 https://astx.com/martins-et-al-the-preclinical-pharmacokinetics-of-tolinapant-a-dual-ciap1-xiap-antagonist-with-in-vivo-efficacy-pharmacol-res-perspect-2024/ 2024-11-19T11:55:27+00:00 monthly 0.2 https://astx.com/2023-ad-pd-poster-development-of-a-cellular-platform-to-study-lysosomal-functions-in-neurodegeneration/ 2024-12-10T14:00:00+00:00 monthly 0.2 https://astx.com/2024-ad-pd-poster-an-assay-platform-to-validate-novel-direct-modulators-of-%ce%b2-glucocerebrosidase/ 2024-12-10T14:01:58+00:00 monthly 0.2 https://astx.com/2022-als-mnd-poster-investigating-the-role-of-neuroinflammation-in-c9orf72-als-using-stem-cell-models/ 2024-12-10T13:22:38+00:00 monthly 0.2 https://astx.com/2024-als-mnd-poster-investigating-microglia-mediated-neuroinflammation-in-stem-cell-models-of-c9orf72-amyotrophic-lateral-sclerosis/ 2024-12-10T14:05:42+00:00 monthly 0.2 https://astx.com/holvey-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2023-j-med-chem-2025/ 2025-01-13T14:12:07+00:00 monthly 0.2 https://astx.com/churcher-et-al-return-to-flatland-nat-rev-chem-2025/ 2025-02-06T17:02:38+00:00 monthly 0.2 https://astx.com/sharp-et-al-integrating-fragment-based-screening-with-targeted-protein-degradation-and-genetic-rescue-to-explore-eif4e-function-nat-commun-2025/ 2025-03-05T09:17:45+00:00 monthly 0.2 https://astx.com/zhang-et-al-the-identification-of-functional-regions-of-mek1-using-crispr-tiling-screens-commun-biol-2025/ 2025-05-20T16:41:07+00:00 monthly 0.2 https://astx.com/2025-aacr-poster-switching-cell-fate-from-senescence-to-apoptosis-by-the-combination-of-a-p53-corrector-with-the-mdm2-antagonist-astx295/ 2025-04-28T14:08:06+00:00 monthly 0.2 https://astx.com/2025-aacr-poster-orthosteric-cdk2-kinase-inhibitors-have-a-distinctive-profile-when-compared-to-genetic-perturbation-of-cdk2-in-ccne1-amplified-and-non-amplified-tumor-cell-lines/ 2025-04-29T19:05:09+00:00 monthly 0.2 https://astx.com/zhang-et-al-the-identification-of-functional-regions-of-mek1-using-crispr-tiling-screens-commun-biol-2025-2/ 2025-06-18T16:48:32+00:00 monthly 0.2 https://astx.com/oruc-et-al-mapping-the-space-of-protein-binding-sites-with-sequence-based-protein-language-models-bioinformatics-2025/ 2025-07-23T08:44:09+00:00 monthly 0.2 https://astx.com/poole-et-al-accelerating-fragment-based-drug-discovery-using-grand-canonical-nonequilibrium-candidate-monte-carlo-nature-communic-2025/ 2025-07-23T09:01:45+00:00 monthly 0.2 https://astx.com/sheth-et-al-measuring-neurofilament-light-in-human-plasma-and-cerebrospinal-fluid-a-comparison-of-five-analytical-immunoassays-clin-chem-lab-med-2025/ 2025-10-14T17:21:51+00:00 monthly 0.2 https://astx.com/downes-et-al-design-modular-synthesis-and-screening-of-58-shape-diverse-3-d-fragments-chemica-science-2025/ 2025-10-14T17:20:27+00:00 monthly 0.2 https://astx.com/twigg-et-al-fragment-to-lead-medicinal-chemistry-publications-in-2024-a-tenth-annual-perspective-j-med-chem-2025/ 2025-12-16T10:18:25+00:00 monthly 0.2 https://astx.com/ma-et-al-from-krasg12d-to-pan-kras-inhibitors-%e2%94%80-a-journey-enabled-by-synthetic-innovation-and-structure-based-drug-design-j-med-chem-2026/ 2026-04-10T15:14:26+00:00 monthly 0.2